Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


PEPTIDE, PROTEIN OR AMINO ACID

Subclass of:

436 - Chemistry: analytical and immunological testing

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
436089000 Amino acid or sequencing procedure 32
436087000 Glycoproteins (e.g., hormone, etc.) 18
Entries
DocumentTitleDate
20080280368PARASITIC HELMINTH CUTICLIN PROTEINS AND USES THEREOF - The present invention relates to: parasitic helminth cuticlin proteins; parasitic helminth cuticlin nucleic acid molecules, including those that encode such cuticlin proteins; antibodies raised against such cuticlin proteins; and compounds that inhibit parasitic helminth cuticlin activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.11-13-2008
20130040395USE OF HALOGENATED DERIVATIVES OF THE CYANOCINNAMIC ACID AS MATRICES IN MALDI MASS SPECTROMETRY - The present invention relates to the use of a halogenated cyanocinnamic acid derivative with the general formula:02-14-2013
20090075388STABLE ISOTOPE-LABELED ALIPHATIC AMINO ACIDS, METHOD FOR INCORPORATING THE SAME IN TARGET PROTEIN AND METHOD FOR NMR-STRUCTURAL ANALYSIS OF PROTEINS - The present invention herein provides a combination of stable isotope-labeled aliphatic amino acids, which permits the structural analysis of a high molecular weight protein, in particular, a high molecular weight protein whose molecular weight exceeds 60 kDa. This is a combination of stable isotope-labeled amino acids which is characterized in that arginine (Arg), glutamine (Gln), glutamic acid (Glu), lysine (Lys), methionine (Met) and proline (Pro) satisfy the following requirements concerning the labelling pattern:03-19-2009
20090061523MASS DEFECT LABELING AND METHODS OF USE THEREOF - Briefly described, embodiments of this disclosure include mass defect labeled peptides, methods of identifying peptides, and the like.03-05-2009
20120184043FLAT BODY IN THE MANNER OF A CHIP CARD FOR BIOCHEMICAL ANALYSIS AND METHOD FOR THE USE THEREOF - At least two microfluidic devices and at least one sensor chip are formed in a flat body. The at least one sensor chip is in direct contact with at least one first microfluidic device. A second microfluidic device in the manner of a pipette is integral with the flat body or connected thereto. The flat body may be used by docking an E-cup by way of a clamping device of the flat body to the flat body and exchanging fluid between the E-cup and the flat body by way of the second microfluidic device.07-19-2012
20120184042Electron Transfer Dissociation for Biopolymer Sequence Analysis - The present invention relates to a new method for fragmenting ions in a mass spectrometer through the use of electron transfer dissociation, and for performing sequence analysis of peptides and proteins by mass spectrometry. In the case of peptides, the invention promotes fragmentation along the peptide backbone and makes it possible to deduce the amino acid sequence of the sample, including modified amino acid residues, through the use of an RF field device.07-19-2012
20100151580Recognitive Hydrogel - Novel recognitive hydrogels and sensors are provided, as well as methods of fabricating and using such hydrogels and sensors. Such recognitive hydrogels may comprise a molecularly imprinted polymer having a binding cavity specific for a triggering molecule and a conductive polymer associated with the molecularly imprinted polymer. Such sensors may comprise the recognitive hydrogels and an impedance sensing component. Such methods may comprise providing a triggering molecule, providing a sensor comprising a molecularly imprinted polymer having a binding cavity specific for the triggering molecule, a conductive polymer associated with the molecularly imprinted polymer, and an impedance sensing component, introducing the triggering molecule into the sensor, and detecting a change in impedance of the recognitive hydrogel with the impedance sensing component.06-17-2010
20100151581PURIFICATION OF IMMUNOGLOBULINS - The present invention relates to a separation matrix comprised of a porous support to which ligands have been immobilised, wherein said ligands comprise at least one aliphatic sulphonamide. The nitrogen of the sulphonamide may be a secondary or tertiary amine. The invention also relates to a chromatography column that contains the described separation matrix, as well as to a method of isolating immunoglobulin-like compounds by adsorption to a separation matrix that comprises aliphatic sulphonamide ligands.06-17-2010
20110195510csPCNA Isoform Modifications And Uses Thereof - Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed.08-11-2011
20110195509TREATMENT OF TH17-MEDIATED AUTOIMMUNE DISEASE VIA INHIBITION OF STAT 3 - Methods for treating autoimmune disease using one or more inhibitor of STAT3 are provided herein. Also disclosed are methods for diagnosing and monitoring autoimmune disease or the propensity to develop autoimmune disease in a subject. The present invention demonstrates that inhibition of STAT3 prevents development of autoimmune disease in vivo. Based on this finding, Stat3 inhibitors can be used to treat and/or diagnose autoimmune disease in a subject.08-11-2011
20100112708Methods and Mixtures Pertaining to Analyte Determination Using Electrophilic Labeling Reagents - This invention pertains to methods, mixtures, kits and/or compositions for the determination of analytes by mass analysis using unique labeling reagents or sets of unique labeling reagents. The labeling reagents can be isomeric or isobaric and can be used to produce mixtures suitable for multiplex analysis of the labeled analytes.05-06-2010
20100075429DIAGNOSTIC MEANS AND METHODS USING TROPONIN T AND NT-PROBNP - The present invention relates to diagnostic means and methods. Specifically, the present invention encompasses a method of diagnosing the cause of cardiac necrosis in a subject comprising determining the amount of a cardiac troponin and the amount of a BNP-type peptide in a sample from a subject suffering from cardiac necrosis and comparing the amount of the cardiac troponin and the amount of the BNP-type peptide to reference amounts, whereby the cause of the cardiac necrosis is to be diagnosed. The present invention further relates to a method of determining whether a subject suffering from cardiac necrosis is susceptible for a therapy against initial heart failure and to a method for determining whether a subject suffering from cardiac necrosis is susceptible for a therapy against coronary heart disease. Also encompassed are diagnostic uses, devices, and kits.03-25-2010
20100075428Monolithic Multinozzle Emitters for Nanoelectrospray Mass Spectrometry - Novel and significantly simplified procedures for fabrication of fully integrated nanoelectrospray emitters have been described. For nanofabricated monolithic multinozzle emitters (NM03-25-2010
20130078728Novel Isobaric Tandem Mass Tags for Quantitative Proteomics and Peptidomics - Compositions and methods of tagging peptides and other molecules using novel isobaric tandem mass tagging reagents, including novel N,N-dimethylated amino acid 8-plex and 16-plex isobaric tandem mass tagging reagents. The tagging reagents comprise: a) a reporter group having at least one atom that is optionally isotopically labeled; b) a balancing group, also having at least one atom that is optionally isotopically labeled, and c) an amine reactive group. The tagging reagents disclosed herein serve as attractive alternatives for isobaric tag for relative and absolute quantitation (iTRAQ) and tandem mass tags (TMTs) due to their synthetic simplicity, labeling efficiency and improved fragmentation efficiency.03-28-2013
20130078727METHODS AND COMPOSITIONS FOR NMR SPECTROSCOPIC ANALYSIS USING ISOTOPIC LABELING SCHEMES - Provided herein are methods and compositions for efficient accumulation of structural information (e.g., three dimensional structural information) for amino acid sequences.03-28-2013
20090124017Sampling Device and Method for the Rapid Detection of Proteins in Mold, Allergens or Other Protein-Containing Substances - Provided is sampling device and method for the detection of protein-containing substances. The sampling device includes a first reagent holder coupled to a second reagent holder by an activating member. Coupled to first reagent holder is a first reagent reservoir and coupled to second reagent holder is a second reagent reservoir. The first reagent reservoir is protected from the ambient environment by a first reagent protector and the second reagent reservoir is similarly protected from the ambient environment by a second reagent protector. After a sample has been obtained from the surface of a sampling object, the application of a sufficient activation force on the activating member places the first reagent reservoir in fluid communication with the second reagent reservoir.05-14-2009
20090215185Non-signal Imidazole Reagents for Mass Spectrometry Analysis of Phosphomonoesters - Analytical chemical reagents termed non-signal imidazoles and a method for their use that provide a host of advantages for analysis of phosphomonoesters are described. The method and compounds of the invention provide a host of advantages for the analysis of phosphomonoester-containing compounds, namely characteristic, multi-analyte detection with high sensitivity and specificity of known and unknown phosphomonoester-compounds simultaneously.08-27-2009
20100105145METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS - The present invention relates to optionally automated methods that may be used to qualitatively and/or quantitatively detect at least one, or for example, two or more different targets in a sample, and kits associated with such methods. The two or more different targets may be detected and distinguished by adding at least one cross-linking agent to the sample in between different steps of a detection procedure. The addition of a cross-linking agent may allow for drastic changes in buffer conditions (i.e. solvent, pH, salt concentration, etc.) or temperature in order to refine a detection procedure with minimal loss of signal. The instant invention is compatible with a variety of detection systems, including immunohistochemistry (IHC), immunocytochemistry (ICC), in situ hybridization (ISH), flow cytometry, enzyme immuno-assays (EIA), enzyme linked immuno-assays (ELISA), blotting methods (e.g. Western, Southern, and Northern), labeling inside electrophoresis systems or on surfaces or arrays, and precipitation, among other general detection assay formats. The invention is also compatible with many different types of samples, targets, probes, and detectable labels.04-29-2010
20100041163COUMARIN-BASED CYANINE DYES FOR NON-SPECIFIC PROTEIN BINDING - Protein dyes whose molecular structure is that of a coumarin moiety coupled to a quaternary ammonium heterocycle through a vinyl or polyvinyl linkage demonstrate the ability to associate with proteins in a non-covalent, non-specific manner at low pH, where the associated form displays a significantly higher fluorescence emission than the unassociated form. This makes the dyes useful as selective labels for proteins at the low pH and eliminates the need for the removal of extraneous components from the medium in which the proteins reside prior to detection.02-18-2010
20100041162USE OF ARYLBORONIC ACIDS IN PROTEIN LABELLING - The present invention relates to the tagging of Histidine in polypeptides with arylboronic acid tagging reagents. The present invention further describes methods and devices to identify proteins in a sample by isolating and identifying Histidine-comprising peptides from one protein sample or a pool of protein samples. The present invention further describes databases of Histidine-comprising peptides from in silico cleaved proteins and their use in the identification of proteins.02-18-2010
20100041161DETECTION AND QUANTIFICATION SYSTEM OF BIOLOGICAL, MATTER CONSTITUTED BY ONE OR MORE OPTICAL SENSORS AND ONE OR MORE LIGHT SOURCES, ASSOCIATED PROCESS AND RELATED APPLICATIONS - The present invention relates to a system and process for detection and/or qualitative and quantitative identification of the biological material, such as specific sequences of nucleic acids or proteins as antibodies, present in biological samples. The system is composed by one or more light sources (02-18-2010
20090325304Mammalian Disease Detection System - A mammalian disease detecting system used to provide a visual indication of a possible disease state includes particles comprised of a material that is substantially clear or transparent to permit the easy visual detection of blood in urine of a mammal. The system also includes additives to permit visually detection of possible disease states or infections in mammals, such additives being of the type that are not reactive with the particular material.12-31-2009
20110008903METHODS AND KITS FOR DETERMINING THE OCCURRENCE OF A LIVER DISEASE IN A SUBJECT - The present application relates to methods for determining the occurrence of a liver disease in a subject by particular polypeptides biomarkers, and to kits using such biomarkers.01-13-2011
20110059540IDENTIFYING SUSCEPTIBILITY OF A SUBJECT TO CARDIAC THERAPY BASED ON DETERMINATION OF A CARDIAC TROPONIN, SCD40L, AND C-REACTIVE PROTEIN - Disclosed is a method for identifying a subject being susceptible to a cardiac therapy based on determination of a cardiac troponin T and the additional determination of C-reactive protein (CRP) or sCD40L (soluble CD40 ligand) in a sample of a subject with stable coronary heart disease and a history of an acute cardiovascular event. Also disclosed is a method for predicting the risk of mortality and/or a further acute cardiovascular event for a subject with stable coronary heart disease and a history of acute cardiovascular event based on the determination of the aforementioned markers. Further disclosed are kits and devices adapted to carry out the disclosed methods.03-10-2011
20110059539L-FABP, NATRIURETIC PEPTIDES, AND CARDIAC TROPONINS IN SUBJECTS IN NEED OF CARDIAC THERAPY - Disclosed is a method for identifying a subject being susceptible to a cardiac therapy, comprising (a) determining the amounts of liver fatty acid binding protein, and at least one further polypeptide from the group of a cardiac troponin and a natriuretic peptide in at least one sample of a subject suffering from heart failure, (b) comparing the thus determined amounts to suitable reference amounts, and (c) identifying a subject being susceptible to a cardiac therapy. Also described is a device and a kit adapted to carry out the method of the present invention. Also described is the use of liver fatty acid binding protein and at least one further polypeptide from the group of a cardiac troponin and a natriuretic peptide for identifying a subject being susceptible to a cardiac therapy.03-10-2011
20130059393AFFINITY/LECTIN CHROMATOGRAPHY METHODS - Methods for making designed carbohydrate affinity columns and lectin columns are provided. Reducing sugar of choice is dissolved in pH 6.0 acetate buffer and injected onto a primary amino group functionality column. The column is washed with pH 6.0 acetate buffer and the column effluent monitored with a variable wavelength UV detector. Lectin columns are made by injecting appropriate lectin to the designed carbohydrate and the lectin binds to this scaffold. The lectin column is formed.03-07-2013
20110014713DETECTION METHOD AND DETERMINATION METHOD FOR DETECTION TARGET - A detection/determination kit with which a substance to be detected or the amount thereof can be rapidly, inexpensively, and easily detected or determined; and a detection/determination method. The kit, which is for detecting a substance to be detected (01-20-2011
20090233373MULTISITE PHOSPHORYLATED PEPTIDE (PROTEIN) RECOGNIZING COMPOUND AND DETECTION METHOD, IMAGING METHOD, ALZHEIMER'S DISEASE DIAGNOSING METHOD AND REAGENT KIT USING THE SAME - There are provided a novel compound which captures a multisite phosphorylated peptide or protein specifically to a phosphorylation site and a method for detecting a multisite phosphorylated peptide or protein using the same. In particular, there are provided a compound which specifically detects an excessively phosphorylated tau protein observed in the brain affected by Alzheimer's disease and a method for diagnosing Alzheimer's disease in vitro or in vivo using the compound. By bringing a metal complex compound having two dipicolylamine (Dpa) moieties and a spacer including a chromogenic or luminescent functional group or atom group into contact with a multisite phosphorylated peptide or protein, the compound recognizes the distance between phosphate groups and specifically binds to the peptide or the protein, and a multisite phosphorylated peptide or protein or a kinase activity is optically detected by measuring the change, or a multisite phosphorylated peptide or protein or kinase activity is imaged by an optical imaging method applying the change in the luminescence.09-17-2009
20120115237ISOLATION OF RNA-PROTEIN COMPLEXES USING CROSS-LINKING REAGENTS AND OLIGONUCLEOTIDES - Provided herein is a method of sample analysis. In certain embodiments, the method comprises: a) cross-linking protein of a cell using a first compound to produce a first cross-linked product comprising cross-linked protein, and RNA; b) contacting the first cross-linked product and a second compound under conditions by which an oligonucleotide portion of the second compound hybridizes to the RNA; c) activating a reaction the first and second compound, thereby covalently crosslinking the oligonucleotide to the cross-linked protein to produce a second cross-linked product; d) isolating the second cross-linked product using an affinity tag; and e) analyzing the isolated second cross-linked product. Compounds for performing the method are also provided.05-10-2012
20120238029COMPOSITION FOR MEASURING THE BINDING AFFINITY BETWEEN NUCLEIC ACID AND TEST SUBSTANCE, AND USE THEREOF - In one embodiment of the present invention, a composition is disclosed for measuring a binding affinity between a nucleic acid and a test substance, which contains an organic fluorescent substance capable of binding to an RNA and which emits fluorescence having an intensity greater while the organic fluorescent substance is liberated from an RNA than while the organic fluorescent substance is bound to an RNA. This enables a highly accurate and easy measurement of a binding affinity between a test substance and a nucleic acid, and allows various substances to be examined as a test substance.09-20-2012
20130164856METHOD OF PROCESSING DRIED SAMPLES USING DIGITAL MICROFLUIDIC DEVICE - Methods are provided for the preparation of a sample using a digital microfluidic platform and the optional subsequent mass analysis of an extracted analyte. A sample is dried, optionally on a solid phase support, and contacted with digital microfluidic array. An analyte present within the dried sample is extracted into an extraction solvent by electrically addressing the digital microfluidic array to transport a droplet of extraction solvent to the dried sample spot. The extracted sample may be dried and subsequently processed on the digital microfluidic array for derivatization. The digital microfluidic device may further include an integrated microfluidic channel having an output aperture, and the method may further include contacting a droplet containing extracted analyte with the microfluidic channel and applying a suitable electric field for generating nano-electrospray, thereby enabling the device to be directly interfaced with a mass analysis device.06-27-2013
20080199964SITE-SPECIFIC INSTALLATION OF METHYL-LYSINE ANALOGUES INTO RECOMBINANT HISTONES - The present invention provides reagents and methods for the introduction of analogues of methyl or acetyl lysine into histone proteins.08-21-2008
20110281366Systems and Methods of Detecting and Demonstrating Hair Damage Via Detection of Protein Loss - Embodiments of a method for demonstrating hair damage comprises eluting protein fragments from a hair sample with an aqueous solution, adding a protein indicating reagent to the aqueous solution to provide a visual indicator corresponding to an amount of protein fragments eluted, and comparing the visual indicator to a scale to determine an amount of eluted protein fragments present in the aqueous solution.11-17-2011
20110281364METHOD AND MARKER FOR DIAGNOSING DIABETES MELLITUS - A process for the diagnosis of diabetes mellitus comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized by the values for the molecular masses and migration times according to Table 1.11-17-2011
20110281365PROTEIN-BASED ASSAYS FOR SCREENING OF THE IGE-RECEPTOR INTERACTION - Embodiments of the invention are related to a polypeptide comprising the amino acid sequence of a human IgE-Fc Cε3-Cε4, wherein said Cε3-Cε4 starts at amino acid 328 and ends at amino acid 547 of said IgE-Fc, and wherein C 328 is A and K 367 is C. Other embodiments concern a second polypeptide comprising the amino acid sequence of a human FcεRIα extracellular region, wherein said extracellular region starts at amino acid 1 and ends at amino acid 176 of said FcεRIα. Still other embodiments are related to a method of identifying a compound that inhibits the binding of an IgE-Fc to a FcεRIα, said method comprising: contacting the polypeptide, wherein said IgE-Fc Cε3-Cε4 sequence is labeled with a fluorophore, and the second polypeptide, with a test compound; and determining whether binding of said polypeptide to said second polypeptide is decreased in the presence of said test compound.11-17-2011
20120107941REAL-TIME MONITOR SOLID PHASE PEPTIDE SYNTHESIS BY MASS SPECTROMETRY - Provided are systems, apparatus, materials and methods for directly monitoring products and intermediates of solid phase chemical synthesis such as solid phase peptide synthesis.05-03-2012
20110171739LIGANDS FOR AGGREGATED TAU MOLECULES - Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example: formula (I) and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.07-14-2011
20100099196PROCESS FOR NORMALIZING THE CONCENTRATION OF ANALYTES IN A URINE SAMPLE - Process for normalizing the concentration of at least one analyte in a urine sample, comprising the following steps: 04-22-2010
20080241947Intestinal folate transporter - Provided is an isolated and purified DNA molecule comprising the coding region of a PCFT cDNA. Also provided is a segment of the above DNA molecule, capable of serving as a primer for amplifying at least a portion of the DNA molecule. Additionally provided is a pair of the above segments that can be used together as forward and reverse PCR primers for amplifying at least a portion of the above DNA molecule. Further provided is an isolated and purified human PCFT protein. Also provided is a method of evaluating the ability of a human to undergo intestinal folate absorption.10-02-2008
20090298184Polypeptide Markers for the Diagnosis of Prostate Cancer - A method for the diagnosis of prostate cancer, comprising the step of determining the presence or absence of at least three polypeptide markers in a sample, wherein the polypeptide marker is selected from markers 1 to 44 and 52 to 78 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 45 to 51 and 79 to 115 (amplitude markers), wherein said sample is a urine sample or seminal fluid sample.12-03-2009
20110217783CLEAVABLE SURFACTANTS AND METHODS OF USE THEREOF - Cleavable compositions that comprise a polar head, cleavable linker, and a hydrophobic tail; and methods for using them to isolate hydrophobic molecules.09-08-2011
20100112709HIGHLY SENSITIVE METHOD FOR DETECTING PROTEIN IN FOOD - A method for accurate and precise measurement of target proteins such as food allergen proteins in the specific foods is provided. The method is a method for immunological measurement of a food allergen protein in a processed food using an antibody against the food allergen protein, comprising adding animal tropomyosin to an assay solution upon measurement.05-06-2010
20090148952Materials and methods for controlling isotope effects during fractionation of analytes - Compositions and methods for controlling or eliminating isotope effects during fractionation of chemically equivalent but isotopically distinct compounds. Isotope coding agents contain heavy isotopes other than deuterium. The invention facilitates intelligent data acquisition. After sample fractionation, isotope abundance ratios are calculated using mass spectrometry, and analytes of interest are identified in real time.06-11-2009
20100267150HDM2 POLYPEPTIDES - The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.10-21-2010
20100267149METHODS OF DETERMINING POTENCY OF CHEMICALLY-SYNTHESIZED OLIGONUCLEOTIDES - Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.10-21-2010
20090087919Method and Apparatus for Measuring Protein Post-Translational Modification - The present invention includes a method for analyzing reactions. The method includes the steps of providing a solution of at least one acceptor chemical and at least one donor chemical. The donor chemical is capable of donating a chemical moiety to the acceptor chemical. The solution further includes at least one controller chemical that affects the reaction between the donor chemical and the acceptor chemical. The solution is then incubated so that a portion of the acceptor chemical reacts with the donor chemical to form an acceptor product. Unreacted donor chemical is separated from the acceptor product. The acceptor product or the donor chemical is then measured using X-ray fluorescence. Another aspect of the present invention includes a method for analyzing protein function. The method includes the steps of providing a solution of at least one acceptor chemical and at least one donor chemical. The donor chemical is capable of donating a chemical moiety to the acceptor chemical. The donor chemical includes a functional group selected from ester, anhydride, imide, acyl halide, and amide. The solution is then incubated so that a portion of the acceptor chemical reacts with the donor chemical to form an acceptor product. Unreacted donor chemical is separated from the acceptor product. The acceptor product or the donor chemical is then measured using X-ray fluorescence. Yet another aspect of the present invention includes a method for analyzing protein function. The method includes the steps of providing a solution of at least one acceptor chemical and at least one donor chemical. The solution is then incubated so that a portion of the acceptor chemical reacts with the donor chemical to form an acceptor product. Unreacted donor chemical is separated from the acceptor product. The acceptor product or the donor chemical is then measured using X-ray fluorescence. An additional analytical method is also used to measure either the acceptor product or the donor chemical.04-02-2009
20090087916Assay method for identifying drug candidate - The present invention provides a method of identifying a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which includes measuring, in the presence of a test compound, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide or a soluble protein in an equilibrium state in a solvent. Moreover, the present invention provides a dissolution promoter to remove peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which contains the compound obtained by the identification method as an active ingredient.04-02-2009
20090087917AUTOMATED PROTEIN ANALYZER - A protein analysis instrument and method are disclosed. The method includes mixing a binding dye composition and a protein sample using a homogenizer, measuring a parameter selected from the group consisting of the speed of the homogenizer and the resistance of the mixture to the homogenizer, adjusting the speed of the homogenizer based upon the measured parameter, pumping unreacted dye composition from the mixture and to a calorimeter, and measuring the absorbance of the dye composition in the calorimeter. Aspects of the invention also include inserting a spout into a sample cup at a position where the spout opening is positioned to avoid foam and precipitate generated by the mixing step and above the bottom of the sample cup and thereafter pumping the dye composition from the mixture in the sample cup through the spout and to a colorimeter.04-02-2009
20090087918DIFFERENTIATION OF ACUTE AND CHRONIC MYOCARDIAL NECROSIS IN SYMPTOMATIC PATIENTS - The present invention relates to a method for diagnosing an acute cardiovascular event comprising the steps of determining the amount of a cardiac troponin in a sample of a subject, determining the amount of a natriuretic peptide in a sample of said subject and diagnosing an acute cardiovascular event by comparing the amounts determined in the previous steps with reference amounts. Moreover, the present invention encompasses a method for differentiating between an acute cardiovascular event and chronic heart failure comprising the steps of determining the amount of a cardiac troponin in a sample of a subject, determining the amount of a natriuretic peptide in a sample of said subject and differentiating between an acute cardiovascular event and chronic heart failure by comparing the amounts determined in the previous steps with reference amounts. Also comprised by the present invention are devices and kits for carrying out such methods.04-02-2009
20100087008Materials and Methods for Isolating Phosphopeptides - Protein phosphorylation is a major post-translational modification and it plays a pivotal role in numerous cellular functions. We present a composition that includes a soluble nanopolymer core functionalized with groups having an affinity for either metal ion or metal oxides which can be used for phosphopeptide enrichment. Exemplary compounds including PolyMAC-Zr, PolyMAC-Fe and PolyMAC-Ti demonstrate outstanding reproducibility, exceptional sensitivity, fast chelation time, and high phosphopeptide recovery from standard mixtures that include phosphorylated peptides. The composition can be used for phosphoproteome isolation from samples of medicinal, diagnostic or biological interest such as malignant breast cancer cells. Such compositions were used for the quantitative analysis of the changes in the tyrosine phosphoproteome in highly invasive breast cancer cells after induction of Syk kinase, a potent suppressor of tumor growth and metastasis. The composition and method disclosed herein offers an efficient and widely applicable tool for phosphoproteomics.04-08-2010
20090124016Nanopatterned surfaces and related methods for selective adhesion, sensing and separation - Nanodimensioned heterogeneous surface compositions and configurations, related systems and methods for sensing particle or analyte interaction therewith.05-14-2009
20100124785WILD-CARD-MODIFICATION TECHNIQUE FOR PEPTIDE IDENTIFICATION - Embodiments of a computer system, a method, and a computer-program product (e.g., software) for analyzing tandem-mass-spectrometry data are described. Using this analysis technique, unanticipated chemical modifications to peptides associated with proteins can be identified. In particular, a modification called a wild-card modification is used to identify the most likely chemical modifications in the peptides. A wild-card modification allows the addition of any mass, typically any integer atomic mass within a range, to any one amino acid residue within a candidate peptide.05-20-2010
20110171736FLUORESCENT ISOTOPE TAGS AND THEIR METHOD OF USE - The present invention provides novel reactive fluorescent compounds that incorporate stable isotopic (deuterium, 13-carbon, 15-nitrogen, 18-oxygen) substitutions. The invention includes the use of these compounds, in combination with non-isotopically substituted analogs, for the purification, identification and relative quantification of proteins, peptides, saccharides, metabolites, and other biologically important compounds by combining liquid chromatography (LC) and mass spectrometry (MS). Fluorescent labeling of target compounds in this manner provides orders-of-magnitude sensitivity enhancement over traditional stable isotope labels, and also affords the possibility of simultaneous multiplexed analysis due to the multiwavelength nature of different fluorophores.07-14-2011
20080206881DIAGNOSTIC MARKER FOR NEURODEGENERATIVE DISEASES - For neurodegenerative diseases such as amyotrophic lateral sclerosis the prediction of disease progression or response to therapy based on phenotypic parameters is very difficult and inaccurate. The measurement of the serum protein carbonyl content allows a quantitative and early diagnosis of these diseases. It enables the monitoring of the disease progression as well as the individual adjustment of the therapy. Furthermore, this diagnostic marker can be used as a readout in animal model based screening methods for new therapeutic approaches and compounds.08-28-2008
20110171738METHOD FOR ESTIMATING THE AMOUNT OF IMMOBILIZED PROBES AND USE THEREOF - The present invention provides a method for estimating an amount of immobilized probes, including the successive steps of: providing a sample on a substrate to form one or more spots of the sample on the substrate, the sample containing particulate substances and probes in a predetermined ratio, the probes being reactive with a predetermined target; measuring the number of the particulate substances contained in at least one of the spots; and estimating the amount of the probes contained in the at least one of the spots from the thus measured number of the particulate substances.07-14-2011
20090286324SERUM MARKERS FOR TYPE II DIABETES MELLITUS - A method for identifying persons with increased risk of developing type 2 diabetes mellitus utilizing selected biomarkers described hereafter either alone or in combination. The present invention allows for broad based, reliable, screening of large population bases and provides other advantages, including the formulation of effective strategies for characterizing, archiving, and contrasting data from multiple sample types under varying conditions.11-19-2009
20130217136DEVICES, METHODS, AND TEST KITS FOR ELECTRONIC ANALYTE ASSAYING - An improved qualitative or semi-quantitative diagnostic test for low levels of any analyte, such as hCG, in a biological sample, such as urine. The test comprises of a test device containing reagents for the detection of the monitored analyte and an electronic reader that measures color development at a detection area of the device. The color development is converted to an electronic or digital signal. Improvements were made to the detection process to optimize the detection of a valid fluid front, increase the detection limit without compromising the reliability and accuracy of the test system, and improve the determination of test result validity.08-22-2013
20080241946Fibroblast growth factor (FGF23) and methods for use - The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.10-02-2008
20080241944METHOD OF MAKING GEL DROP PROTEIN BIOCHIPS - A method of making a gel drop protein chip by transferring proteins, which were obtained from a cellular lysate, partitioned using two-dimensional, protein fractionation, and mixed with a polymeric matrix solution containing acrylamide/bis and glycerol, to an array; a method of making a gel drop protein chip by transferring proteins, which were derivatized with N-hydroxysuccinimide ester of N-methacryloyl-6-aminocaproic acid (NHS monomer), and mixed with a polymeric matrix solution containing acrylamide/bis and glycerol, to an array; a gel drop protein chip containing proteins in a polymeric matrix solution containing acrylamide/bis glycerol; a method of using the gel drop protein chip to interrogate a sample; and a protein derivatized with the NHS monomer.10-02-2008
20080286877Displacement assay for detection of small molecules - Complex of an anti-cocaine aptamer and the dye diethylthiotricarbocyanine behaves as a calorimetric sensor with attenuation in absorbance at 760 nm for cocaine in the concentration range of 2-5000 μM. Mechanistic studies indicate an intermolecular displacement of the dye as the mechanism of action of the sensor. As the dye is insoluble in buffer, cocaine binding can be detected as displaced dye precipitates and supernatant decolorizes.11-20-2008
20080293148Method and System for Detecting Bio-Element - Disclosed are system and method for measuring a bio-element capable of accurately detecting whether a bio-element such as protein, gene and the like is present in an atmosphere or vapor phase having controlled temperature and humidity thereof and measuring a content of the bio-element. According to an embodiment of the invention, the method comprises steps of preparing a cantilever sensor having a plurality of cantilevers; measuring a basis resonant frequency for the plurality of cantilevers; reacting the cantilevers with a sample including a bio-element; measuring resonant frequencies of the cantilevers after the reaction, in a closed system that is isolated from an exterior environment and temperature and humidity thereof are controlled to a specific state; and calculating variations of the resonant frequencies of the cantilevers before and after the reaction to carry out a quantitative analysis of the bio-element included in the sample.11-27-2008
20080293149ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.11-27-2008
20080305552ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.12-11-2008
20080305551Method for Diagnosing a Pervasive Developmental Disorder - A method for diagnosing a pervasive developmental disorder, such as autism, comprising obtaining a sample of cerebrospinal fluid from a subject; obtaining a sample of serum from a subject; testing the cerebrospinal fluid of the subject for a concentration of TNF-α; testing the serum of the subject for a concentration of TNF-α; and positively diagnosing a pervasive developmental disorder when the concentration ratio of TNF-α in the cerebrospinal fluid of the subject to TNF-α in the serum of the subject exceeds approximately 2:1 over normal control concentrations.12-11-2008
20080213909PHARMACEUTICAL PACKAGING ASSAY - A pharmaceutical packaging assay for the determination of drug adsorption to the packaging surface(s) is described. The assay described utilizes fluorescent labeling of drugs in various formulations to determine the best packaging surface for drug stability as a function of adsorption.09-04-2008
20100136700METABOLIC SYNDROME AND HPA AXIS BIOMARKERS FOR MAJOR DEPRESSIVE DISORDER - Materials and methods for using combinations of metabolic syndrome and HPA axis biomarkers for monitoring major depressive disorder.06-03-2010
20100144044IDENTIFICATION OF PHOSPHORYLATION SITES IN POLYPEPTIDES BY EMPLOYMENT OF URANYL PHOTOCLEAVAGE - The present invention relates to a method of cleaving a polypeptide at one or more phosphorylated residues. Said cleavage is induced by irradiation and is dependent on the presence of uranyl. The method is useful for analysis of phosphoproteoms and also for protein purification. The method also relates to a method of protein purification, wherein the phosphorylated protein is immobilized on a column said immobilization being dependent on uranyl.06-10-2010
20090093061Protein separation device - The invention provides a protein separation device comprising a chaperone protein immobilised on a substrate. In one embodiment, the chaperone protein is an Hsp60 chaperone, preferably a group one chaperone, preferably GroEL. The invention also provides a method for isolating a protein from a biological sample using a protein separation device of the invention.04-09-2009
20100144045CHIRAL SELECTORS FOR SEPARATING ENANTIOMERS OF A COMPOUND - The invention relates to the use of compounds as new chiral selectors for separating the optical or enantiomeric isomers of a compound, wherein the chiral selector comprises at least one compound of formula (I): and at least one metal ion, for example Cu06-10-2010
20090137051Monoclonal Antibodies Directed Against The Microtubule-Associated Protein Tau - A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.05-28-2009
20090142849Stable Oxygen Isotope Labeling of Pre-existing Phosphoryl Groups on Phosphomolecules for Modification-Specific Mass Spectrometry - The present invention relates to the production and use of phosphate-specific marker ions labeled with one or more stable oxygen isotopes for analysis of phosphopeptides and other phosphorylated biological and synthetic molecules.06-04-2009
20080318326Method of Manufacture - The invention relates to methods of preparing a bilayer lipid membrane on a support matrix as well as a matrix preloaded with a protein and methods to achieve same. Steps used include hydration, pore infiltration, application of bilayer lipid membrane forming solutions and application of protein containing solutions. The methods and matrix produced are able to form and maintain a stable membrane. A further advantage is that the matrix may be pre-loaded with protein and then stored for use at a later date effectively stabilising the protein for later use.12-25-2008
20090325303PROCESS - A method for detecting a presence of an abnormal component in a keratin sample taken from a subject suffering from a pathological state comprising the steps of exposing the keratin sample to a swelling substance so as to penetrate the keratin sample thereby producing a derived chemical substance; obtaining data from the derived chemical substance; comparing the data obtained from the derived chemical substance with a second group of data contained in a reference database so as to identify the presence of the abnormal component in the keratin sample; whereby detection of the abnormal component is consistent with a presence of the pathological state in the subject.12-31-2009
20090053818Quantitative proteomics with isotopic substituted raman active labeling - A labeling reagent having a distinct Raman, or surface enhanced Raman, spectral signature is used for the control and analysis samples. The labeling reagents can be fluorescent dyes with different isotopic substituents, such as the substitution of some hydrogen atoms for deuterium atoms. Such labeling does not have any detectable effect on separation retention. Raman spectroscopy is used for detection purposes. By combining SERS and SERRS, a concentration ratio prediction error of less than 3% can be obtained over four orders of magnitude of total concentration with up to a factor of 3 concentration ratio range. The method is reliable, reproducible and more sensitive than methods based on absolute SERS/SERRS intensity correlations, with no internal standard, or using a different molecule (rather than an IEIS) as a SERS/SERRS internal standard.02-26-2009
20090081799ANALYTE EVALUATION DEVICE AND ANALYTE EVALUATION METHOD - An analyte evaluation device includes: a light irradiator for inducing fluorescence emission from an analyte; a carrier for positioning the analyte; and a fluorescence detector for receiving the fluorescence, wherein the light irradiator and the fluorescence detector are situated on mutually opposing sides of the carrier, light irradiated from the light irradiator can be passed through to a side where the fluorescence detector is located, and fluorescence emission from the analyte can be induced by the transmitted light while keeping the transmitted light from directly irradiating a fluorescence detecting element of the fluorescence detector.03-26-2009
20090081800Selective resonance of chemical structures - Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.03-26-2009
20090081797REACTIVE SURFACE ON A POLYMERIC SUBSTRATE - Plasma treated cyclic polyolefin copolymer surfaces having enhanced binding density for binding biologically active agents and cells are provided. These plasma treated cyclic polyolefin copolymer surfaces may be further enhanced for binding biologically active agents or cells by the application of conjugates. Methods of making and characterizing treated polymer surfaces are also provided.03-26-2009
20110143443Isolsted Monoclonal - Associated Protein Tau and Kit - A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.06-16-2011
20100003763LONG WAVELENGTH THIOL-REACTIVE FLUOROPHORES - Reactive fluorescent dyes compositions and methods of using same are disclosed. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed having thiol-reactive groups. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed that exhibit a fluorescence emission of at least about 575 nm. Biosensors are disclosed having a binding protein and a squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus.01-07-2010
20100248378METHOD AND MARKER FOR DIAGNOSING DIABETES MELLITUS - A process for the diagnosis of diabetes mellitus comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized by the values for the molecular masses and migration times according to Table 1.09-30-2010
20100248377DETECTION OF CONTRAST MEDIUM-INDUCED NEPHROTOXICITY - The present invention relates to a method for diagnosing contrast medium-induced nephrotoxicty in a subject based on comparing the amount of urotensin II and/or adiponectin in a sample of the subject obtained after administration of the contrast medium to the amount of urotensin II and/or adiponectin in a sample of the subject prior to administration of the contrast medium. Further encompassed by the present invention are a kit and a device for carrying out the method of the present invention.09-30-2010
20090053819Methods and Systems for Protein and Peptide Evidence Assembly - The present teachings provide methods and systems for the identification of proteins via peptide analysis. Some embodiments analyze proteins identified by analysis techniques such as mass spectrometry and build protein groups out of results. Groups can be formed by collecting like proteins and examining the group so as to identify if it is likely that only one form of a protein is present or, if there is enough evidence to support the presence of alternate forms. Various embodiments provide visual reports that can be interactive. These reports can allow a user to visualize relationships between proteins both intra- and inter-group. Methods are also introduced that can reduce the identification of false positives by taking into account a priori information.02-26-2009
20090053817FIXED CHARGE REAGENTS - The present invention relates to fixed charge reagents and kits for use in tandem mass spectrometry methods involving multiplex analysis. The compounds of the invention are phenacylamide compounds. The invention also relates to methods for the quantification of for example peptides and proteins by tandem mass spectrometry techniques using said reagents and kits. The reagents and kits of the invention enable multiplexed analysis of several samples in one experiment.02-26-2009
20090117662Mutants of IGF Binding Proteins and Methods of Production of Antagonists Thereof - The present invention provides a crystal suitable for X-ray diffraction, comprising a complex of insulin-like growth factor I or II (IGF) and a polypeptide consisting of the amino acids 40-92 of IGFBP-5 or a fragment thereof consisting at least of the 905-07-2009
20090137052PHOSPHOPEPTIDE ANALYSIS METHOD - According to the present invention, a matrix reagent prepared by adding methylenediphosphonic acid (MDPNA) having two phosphonic acid groups as an additive to a matrix of 2,5-dihydroxybenzoic acid (DHBA) is used for the preparation of a sample. By using the sample according to the present invention, it is possible to achieve a higher peak intensity of phosphopeptide as compared with a sample in which DHBA is solely used as a matrix without using an additive, or a sample in which phosphoric acid (PA) is used as an additive in addition to DHBA. Further, use of the sample according to the present invention enables the detection of peptides that cannot be detected in a case of the phosphoric acid-added sample.05-28-2009
20090004749METHOD AND KIT FOR DETERMINING THE AMOUNT OF DNA BINDING PROTEIN - A kit for determining a quantity of a target DNA binding protein in a liquid sample by using a fluorescence correlation spectroscopy, comprising a first measuring reagent including a fluorescent-labeled nucleic acid probe and a first unlabeled nucleic acid probe, a second measuring reagent including the fluorescent-labeled nucleic acid probe and a second unlabeled nucleic acid probe, wherein the target DNA binding protein is capable of binding to the fluorescent-labeled nucleic acid probe and the first unlabeled nucleic acid probe, and is not capable of binding to the second unlabeled nucleic acid probe; and a method for determining a quantity of a target DNA binding protein in a liquid sample is also disclosed.01-01-2009
20090209041Peptides and methods for inhibiting amyloid formation - A peptide comprising at least 5 amino acid residues and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO: 7 as well as pharmaceutical compositions, kits and methods for diagnosing and treating amyloid associated diseases.08-20-2009
20080261316Compositions and Methods For Enhancing the Identification of Prior Protein Prpsc - A method for purifying PrP10-23-2008
20080261315Colorimetric and Fluorometric Determination of Homocysteine and Cysteine - Colorimetric and fluorometric methods are disclosed for the rapid, accurate, selective, and inexpensive detection of homocysteine, or of homocysteine and cysteine, or of cysteine. The methods may be employed with materials that are readily available commercially. The novel methods are selective for homocysteine, for cysteine, or for total homocysteine and cysteine, and do not cross-react substantially with chemically-related species such as glutathione. The homocysteine-selective method does not have substantial cross-reactivity to the very closely related species cysteine. The cysteine-selective method does not have substantial cross-reactivity to the very closely related species homocysteine. The methods may be used, for example, in a direct assay of human blood plasma for homocysteine levels.10-23-2008
20100273267DIAGNOSIS OF ABDOMINAL AORTIC ANEURYSM USING BIOMARKERS - The invention relates to proteins associated with abdominal aortic aneurysm (AAA). These proteins, which are present in blood, are expressed in individuals with AAA at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AAA. The invention provides methods for determining the efficacy of preventive treatment for AAA. The invention provides methods for monitoring the progression of AAA10-28-2010
20130122599Fragmentation Reagents For Mass Spectrometry - A mass spectrometry electron transfer dissociation reagent comprising an unsaturated compound having a Frank Condon factor between 0.1 and 1.0 and an electron affinity having a positive value between 0.1 to 150 kJ/mol.05-16-2013
20130122600Quenched Fluorophores Conjugated to Peptides Via Linkers Containing Dithio Groups - Disclosed are dithio compounds that include a quenched fluorophore and a non-fluorophore peptide linked via a dithio bond to the fluorophore. The dithio compounds may be used in methods for detecting thiol-containing compounds or dithio-containing compounds. The dithio compounds also may be used as cellular probes where the peptide portion of the compounds targets the compounds to a specific cellular location.05-16-2013
20100261284USING GDF 15 TO ASSESS PATIENTS PRESENTING TO EMERGENCY UNITS - Described is a method of identifying if a subject is to be admitted to the hospital or intensive care unit, the method comprising a) determining the amount of GDF 15 in a sample of the subject, and b) comparing the amount of GDF 15 determined in step a) to a reference amount, whereby a subject to be admitted to the hospital or intensive care unit is to be identified. Also described is a method for predicting the risk of mortality based on determining the amount of GDF 15 in a subject. Also described are devices and kits for carrying out the aforementioned methods.10-14-2010
20100261283SURFACTANT PROTEINS B AND D FOR DIFFERENTIAL DIAGNOSIS OF DYSPNEA - The present invention relates to means and methods for differentially diagnosing the cause of acute shortness of breath. Specifically, contemplated is a method of differentiating in a subject suffering from shortness of breath (dyspnea) between a pulmonary disease and a cardiovascular complication as the cause of the dyspnea comprising the steps of determining the amount of SP-B and SP-D in a sample of a subject and comparing the amounts of SP-B and SP-D with reference amounts, whereby it is differentiated between a pulmonary disease and a cardiovascular complication as the cause of the dyspnea. Furthermore, the present invention encompasses a device and a kit adopted for carrying out the aforementioned method.10-14-2010
20100159608ASSESSING HEART FAILURE IN PATIENTS WITH ATRIAL FIBRILLATIN USING GDF-15 AND NATRIURETIC PEPTIDES - The present invention is concerned with methods and devices for medical diagnosis. Specifically, it relates to a method of diagnosing heart failure in a subject exhibiting atrial fibrillation, the method comprising determining the amount of GDF-15 in a sample of the subject and comparing the amount of GDF-15 with a suitable reference amount whereby heart failure is to be diagnosed. Moreover, the present invention relates to a diagnostic device and a kit for carrying out the aforementioned method.06-24-2010
20110059538DIFFRACTION GRATINGS COMPRISING POROUS MATERIALS AND DIFFRACTION-BASED SENSORS COMPRISING POROUS MATERIALS - Diffraction gratings comprising a substrate with protrusions extending therefrom. In one embodiment, the protrusions are made of a porous material, for example porous silicon with a porosity of greater than about 10%. The diffraction grating may also be constructed from multiple layers of porous material, for example porous silicon with a porosity of greater than about 10%, with protrusion of attached thereto. In some embodiments the protrusions may be made from photoresist or another polymeric material. The gratings are the basis for sensitive sensors. In some embodiments, the sensors are functionalized with selective binding species, to produce sensors that specifically bind to target molecules, for example chemical or biological species of interest.03-10-2011
20110059537METHOD FOR ESTIMATING RISK OF ACUTE KIDNEY INJURY - Methods and products for identifying subjects at risk of acute kidney injury (AKI) are provided according to the invention. Included, for instance, are diagnostic kits and methods involving the use of at least two AKI associated markers.03-10-2011
20100159607IL1RL-1 AS A CARDIOVASCULAR DISEASE MARKER AND THERAPEUTIC TARGET - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.06-24-2010
20100216249DNA-Based Biosensors - There is described a method of detection of the protein-dependent coincidence of DNA in a sample which comprises detection using luminescence of one or more luminophores introduced into DNA with one, two or more DNA fragments which fragments are bound using one or more DNA-binding proteins.08-26-2010
20100227410MULTI-IMMUNOAFFINITY BASED ANTIGEN IDENTIFICATION - The present invention relates to methods for identifying antigens from complex analyte samples. More specifically, the invention relates to methods for identifying antigens recognized by monoclonal antibodies in a complex analyte sample. The methods of this invention use a first affinity chromatography via a “multiaffinity” step and a second, “singleaffinity” step that implements parallel affinity chromatography.09-09-2010
20100227411POLYPEPTIDE MARKERS FOR THE DIAGNOSIS OF PROSTATE CANCER - A method for the diagnosis of prostate diseases, comprising the step of determining an amplitude or the presence or absence of at least one polypeptide marker in a sample, wherein said polypeptide marker is selected from markers 1 to 141, which are characterized by values for the molecular masses and migration times.09-09-2010
20100240138DIAGNOSIS OF AGE-RELATED MACULAR DEGENERATION USING BIOMARKERS - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD.09-23-2010
20130217137SYSTEMS AND METHODS FOR PROTEIN MELT ANALYSIS USING DIPYRROMETHENEBORON DIFLUORIDE COMPOUNDS - According to the present teachings, systems and methods for protein melt analysis are provided that utilizing a dye. In some embodiments, a method comprises preparing a sample by mixing at least one protein with a dye, and applying a controlled heating, while recording the fluorescence emission of the sample.08-22-2013
20100144046CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION - A complex containing a transition metal ion and a plurality of donor ligands each of which is fully coordinated to the transition metal ion and is either a nitrogen donor ligand or a cyclometalated donor ligand, such that at least one of the donor ligands is a cyclometalated donor ligand bears one or more reactive groups connected to at least one of the donor ligands through a linker that includes a chain of four or more atoms. The linker offers advantages that make the complex particularly effective in labeling biomolecules and in multiplex analyses.06-10-2010
20100210022Systems for and Methods of Detecting Mastitis - Method and systems for determining if one or more animals has mastitis and for monitoring animals and the quality of the milk they produce are disclosed. Systems and test assays disclosed are used to determine the quantity of proteasomes and proteins thereof, the activity of proteasome enzymes, the quantity of proteasome bound and regulating proteins, and the quantity of ubiquinated protein. Components and reagents for use in the systems and assays are also disclosed.08-19-2010
20090258426Preferred segments of neural thread protein and method of using the same - The invention is directed to preferred repeat sequences of Neural Thread Protein (NTP), peptides, mimetics, antibodies, and nucleic acids of the preferred sequences, and diagnostic and therapeutic methods of using such preferred NTP sequences.10-15-2009
20110129936D-DIMER, TROPONIN, AND NT-PROBNP FOR PULMONARY EMBOLISM - The present invention relates to a method of diagnosing acute pulmonary embolism (PE) in a subject including a) determining the amount of fibrin-fibrinogen degradation products, in particular D-dimer in a sample of the subject; b) determining the amount of a natriuretic peptide in a sample of the subject; c) determining the amount of a cardiac troponin in a sample of the subject; and d) comparing the amounts determined in steps a) to c) to reference amounts, thereby establishing the diagnosis. Included is also a method of deciding on a therapy of a subject diagnosed with PE and a method of monitoring the therapy.06-02-2011
20110117658METHOD OF RATIONAL-BASED DRUG DESIGN USING OSTEOCALCIN - The invention relates to a method of identifying a compound that affects osteocalcin activity, comprising obtaining a 3D structure of osteocalcin or a fragment thereof, designing a compound to interact with, or mimic, the 3D structure of osteocalcin or fragment thereof, obtaining the compound, and determining whether the compound affects osteocalcin activity.05-19-2011
20110171737PROTEIN ENGINEERING - Methods of optimizing mRNA sequences for expression in host cells are provided. Methods of determining the stability of a protein are also provided. Methods of determining the affinity of a ligand for a protein are also provided.07-14-2011
20090035868RAPID PROTEIN LABELING AND ANALYSIS - The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein. Following the labeling step, the proteins within the mixture can be separated and analyzed. In a further embodiment, a tag binding fluorogenic reagent that can bind to a tag on a tagged protein is added to specifically label the protein of interest.02-05-2009
20110008899APPARATUS FOR DETERMINING THE COMPOSITION OF A SPECIMEN, IN PARTICULAR ONE CONTAINING PROTEIN - An apparatus and a method for determining the composition of a protein-containing specimen has a combustion chamber for the combustion of the specimen, an exhaust gas line connected to a combustion chamber heated by a heating device, a combustion control device, an oxygen inflow line opening into the combustion chamber with an oxygen inflow valve, which can be operated by means of the control device, and an analyser connected to the combustion chamber. An oxygen sensor connected to the control device determines the oxygen content in the combustion gases. The oxygen content is determined in time intervals or continuously during combustion. If a pre-specifiable concentration of oxygen is not achieved, a definable quantity of oxygen is injected into the combustion chamber by the oxygen inflow valve. After complete combustion of the specimen, the combustion gases are delivered to the analyser to determine nitrogen, carbon dioxide, sulphur dioxide and/or water content.01-13-2011
20110008902METHOD AND DEVICE FOR STUDYING TRANSPORT OF AN AGENT ACROSS A BILAYER MEMBRANE IN BIOANALYTICAL SENSOR APPLICATIONS - The present invention provides a method for studying transport of an agent across a membrane comprising the steps a) providing at least one surface with a bilayer structure tethered to the surface, said bilayer structure comprising a detection volume, b) contacting the bilayer with at least one agent to be analysed, and c) detecting a change in refractive index in the detection volume resulting from transportation of the agent across the membrane. Further there is provided a device comprising a) at least one surface, b) at least one bilayer structure tethered to the surface, and c) at least one sensor capable of detecting a change in refractive index in a detection volume, wherein the bilayer structure encloses a first volume of the detection volume and wherein the volume not enclosed by the bilayer structure but within the detection volume is a second volume and wherein the ratio between the first volume and second volume is above about 0.001.01-13-2011
20110008900DEPLETION OF PLASMA PROTEINS - This invention relates to methods of analysis, and in particular to methods for the preliminary fractionation of samples in which low abundance molecules of interest, for example proteins, polysaccharides or fatty acids, are present together with more abundant molecules of little or no interest. In particular, the invention relates to methods of depletion of high abundance proteins from biological samples. Products and kits for use in the method are also disclosed, and form part of the invention. In one aspect, the invention provides a method of depleting a high-abundance molecule from a biological sample, comprising the steps of a) subjecting the sample to affinity depletion using an affinity support with high affinity for a high abundance molecule, and/or b) immunodepletion using an affinity support coupled to an antibody directed against whole or previously fractionated plasma or serum.01-13-2011
20110008901APOLIPOPROTEIN CIII IN PRE- AND TYPE 2 DIABETES - The present invention is directed to diagnosing, determining, and/or monitoring type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by detecting levels and modulations of ApoCIII and its variants. The present invention is also directed to methods for identifying and evaluating therapeutic treatments for type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by monitoring ApoCIII and its variants.01-13-2011
20110014714METHOD FOR SELECTIVE LABELING OF PROTEIN PRODUCED BY IN VITRO TRANSLATION BY USING A MARKER FROM TRNA PREPARED BY USING IN VITRO TRANSCRIPTION - The present invention relates to a method for the preparation of a labeling material (labeling agent) usable for non-radioactive selective labeling of proteins produced by in vitro translation with fluorophore or biotin; and a method for selective labeling of proteins produced by in vitro translation using the said labeling material. More specifically, the present invention provides a method for preparing a labeling material usable for selective labeling of a target protein produced only from the gene added to the cell-free protein synthesis reaction mixture by an experimenter without labeling pre-existing proteins in the reaction mixture, for which only one type of tRNA prepared by in vitro transcription is used instead of “total tRNA mixture”. The present invention also provides a method for labeling of the protein produced by in vitro translation by using the labeling material prepared by the above method. According to the present invention, the preparation of a labeling material becomes easier and the protein labeled with the labeling material of the present invention provides much improved signals than the protein labeled with the labeling material of the conventional method prepared by using “total tRNA mixture” as a tRNA material.01-20-2011
20110033941RISK ANALYSIS IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME - The present invention relates to a method for identifying a subject being susceptible to a metabolic syndrome related therapy based on determining the amounts of adiponectin, retinol binding protein 4, and proinsulin in a sample of a subject, and comparing the thus determined amounts to suitable reference amounts. Moreover, the present invention relates to a method for predicting the risk of developing a metabolic syndrome in an apparently healthy subject based on determining the aforementioned markers in a sample from the subject. Also encompassed by the present invention are kits and devices adapted to carry out the methods of the present invention.02-10-2011
20110033942PREDICTING RENAL FAILURE IN DIABETES PATIENTS BASED ON PLACENTAL GROWTH FACTOR AND SOLUBLE FLT-1 - Disclosed is a method for predicting the risk of developing renal failure or mortality for a subject suffering from diabetes mellitus. More specifically, a method is disclosed for predicting the risk of developing renal failure for a subject suffering from diabetes mellitus, the method including the steps of determining the amounts of PLGF and sFlt-1 in a sample of a subject suffering from diabetes mellitus and comparing the amounts of PLGF and sFlt-1 determined with reference amounts of PLGF and sFlt-1, whereby the risk of developing renal failure is predicted. Also disclosed are diagnostic devices and kits for carrying out the aforementioned methods.02-10-2011
20110129935PROTEIN STABILITY ASSAY USING A FLUORESCENT REPORTER OF PROTEIN FOLDING - The invention relates to methods and compositions for assessing protein stability, including improved assays for distinguishing between soluble and aggregated proteins. The methods and compositions include measuring residual fluorescence of a fusion protein in a soluble fraction as an indicator of protein solubility, and monitoring fluorescence quenching of a fusion protein as an indicator of protein stability. The fusion protein may comprise an amino acid sequence of a protein of interest, a peptide linker amino acid sequence and an amino acid sequence of a fluorescent marker protein.06-02-2011
20090311792Fibroblast growth factor (FGF23) and methods for use - The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.12-17-2009
20090081798Protein S Functional Assay - The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.03-26-2009
20120244624ANALYZING METHOD AND SYSTEM FOR TEST STRIPS - An exemplary test strip reading and analyzing system includes a test strip unit, a mobile device and a remote computing apparatus. The test strip unit includes at least one tested-object reacting region. The mobile device includes an image capture module for capturing a test-strip image of the test strip unit and a transmission module electrically coupled to the image capture module. The remote computing apparatus, installed with a test strip analyzing system, is for analyzing the test-strip image and accordingly generating an test report. The test-strip image captured by the image capture module is transmitted to the remote computing apparatus through the transmission module; and the test report generated by the remote computing apparatus is consequently transmitted to the mobile device.09-27-2012
20120190120PROTEIN DETECTION REAGENTS AND METHODS WITH DYES AND DEXTRINS - The invention provides reagents, methods and kits for detection of proteins and quantitative determination of protein concentration. The reagents comprise a protein-complexing dye, such as a Coomassie dye and one or more dextrins, for the elimination of interference caused by detergents.07-26-2012
20100068819COMPOUNDS AND METHODS FOR DOUBLE LABELLING OF POLYPEPTIDES TO ALLOW MULTIPLEXING IN MASS SPECTROMETRIC ANALYSIS - The present invention describes double labelling reagents with both an isotopic and isobaric label component suitable for differentially labelling different—protein samples. After labelling of the individual protein samples, all samples are pooled. Peptides from the pooled samples are isolated and analysed by mass spectrometry for determining the relative concentration of each differentially double-labelled polypeptide.03-18-2010
20100055797Nano-construction processes and analytical processes - A process for assembling molecules on a surface, the process comprising: providing a probe having a variable-temperature tip; providing a first material, which is optionally on a first surface of a substrate; bringing the tip of the probe into contact with the first material, whereby molecules of the first material are transferred to the tip; and moving the tip of the probe to a position above a surface of a second material (the second surface); then heating the tip of the probe to a temperature T2, at which the first material will transfer from the tip to the surface of the second material. Analytical process using this method are also disclosed.03-04-2010
20100062538IDENTIFYING AND COUNTING PROTEINS IN A SAMPLE - The proteins in a cell are preferably proteolytically cleaved and chemically attached to another peptide of unique and known sequence. In one embodiment of the invention, peptide-linker-peptide triplets are synthesized with linker molecules such as polyhistidine. In a more preferred embodiment of the invention, peptide-mass differentiated group (MDG) constructs are synthesized. The MDG's may be obtained from a library of oligo-N(K)-peptides synthesized on resin beads, wherein N is the length of the peptides (with a default value of 4) and K is the number of alternative amino acids (with a default value of 10) at each position. Coupling between given peptides and linkers or MDG's creates recombinants with different overall masses that migrate separately in chromatographic separations. The peptides-linker/MGD's recombinants may be purified and sequenced by MS/MS analysis. The resulting purified and sequenced peptides are then counted, and the ratios of the different peptides within and/or between samples obtained.03-11-2010
20110076778SOLUBILIZATION OF PROTEINS IN REVERSE MICELLES BY EXTRACTION FROM A SOLID SUPPORT - A general method for solubilizing proteins by direct extraction of an immobilized protein into a reverse micelle solution is disclosed. The reverse micelle protein solutions are amenable to analysis using spectroscopic techniques, particularly NMR spectroscopy.03-31-2011
20110081725ASSESSMENT OF COMPLICATIONS OF PATIENTS WITH TYPE 1 DIABETES - Described is a method of predicting a risk of a diabetes type 1 patient to suffer from one or more complications selected from cardiovascular complications, terminal renal failure, and death, the method involving a) determining the amount of a cardiac troponin, preferably troponin T, in a sample of a diabetes type 1 patient; and optionally b) determining the amount of a natriuretic peptide, preferably NT-proBNP, in a sample of a diabetes type 1 patient; and c) comparing the amount of the cardiac troponin and optionally the natriuretic peptide determined in steps a) and b) to reference amounts, and establishing a prediction. Also described are devices and kits for carrying out the aforementioned methods.04-07-2011
20110076777REACTION APPARATUS AND PROCESS - A new reaction apparatus including a capillary having an inner surface to which a probe molecule that specifically binds to an analyte is immobilized and achieving a highly efficient reaction using a small amount of a sample and a process of the reaction are provided. The reaction apparatus includes a capillary having an inner surface to which a probe molecule that specifically binds to an analyte is immobilized; a passage allowing a fluid discharged from one end of the capillary to flow to the other end of the capillary; a columnar magnetic body that is disposed in a fluid containing the analyte in the capillary and/or the passage in the state that the fluid fed in the capillary can circulate via the passage; end-fixing means for fixing one end of the columnar magnetic body in the capillary and/or the passage by a DC magnetic field; and end-moving means for moving the other end of the columnar magnetic body by an AC magnetic field such that the fluid circulates via the passage.03-31-2011
20110151568Assay for Monitoring Parathyroid Hormone (PTH) Variants by Tandem Mass Spectrometry - Methods are described for monitoring the amounts of PTH variants in a biological sample by digesting the sample to produce surrogate peptides specific to the targeted PTH variants, and detecting and quantifying the surrogate peptides by selective reaction monitoring (SRM) mass spectrometry, using a set of precursor-to-product ion transitions optimized for sensitivity and selectivity. The PTH variants, or a portion thereof, may be concentrated in the sample by means of immunoaffinity capture or other suitable technique. The mass spectrometric method described herein enables the concurrent measurement of peptides representative of a plurality of targeted PTH variants in a single assay.06-23-2011
20100304493SELECTIVE ENRICHMENT OF POST-TRANSLATIONALLY MODIFIED PROTEINS AND/OR PEPTIDES FROM COMPLEX SAMPLES - The present invention relates to the selective enrichment of post-translationally modified proteins and/or peptides from complex samples by combining a particular protein/peptide labeling and fractionation strategy with specific chemical and/or enzymatic reactions targeting the post-translational modification to be analyzed. More specifically, the invention relates to methods for the enrichment and/or separation of phospho-proteins and/or -peptides, and particularly for the discrimination between different subsets of phospho-proteins and/or -peptides in complex samples.12-02-2010
20100112707Biosensor - The invention relates to a biosensor solution in which the biosensor comprises at least one sol-gel response region pattern doped with a biological signature molecule and printed on the biosensor, and at least one micro-channel for transporting material to said at least one sol-gel response region pattern.05-06-2010
20100081203FLUORESCENT ISOTOPE TAGS AND THEIR METHOD OF USE - The present invention provides novel reactive fluorescent compounds that incorporate stable isotopic (deuterium, 13-carbon, 15-nitrogen, 18-oxygen) substitutions. The invention includes the use of these compounds, in combination with non-isotopically substituted analogs, for the purification, identification and relative quantification of proteins, peptides, saccharides, metabolites, and other biologically important compounds by combining liquid chromatography (LC) and mass spectrometry (MS). Fluorescent labeling of target compounds in this manner provides orders-of-magnitude sensitivity enhancement over traditional stable isotope labels, and also affords the possibility of simultaneous multiplexed analysis due to the multiwavelength nature of different fluorophores.04-01-2010
20100062537Polypeptide Markers for the Diagnosis and Evaluation of Pelvi-Ureteric Junction Obstruction (PUJO) - A process for diagnosing pelvi-ureteric junction obstruction (PUJO), comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein said polypeptide marker is selected from markers 1 to 277 (frequency markers), or of determining the amplitude of at least one polypeptide marker selected from markers 278-308 (amplitude markers), which are characterized by values for the molecular masses and migration times (CE times).03-11-2010
20120171773Temperature Control Of Enrichment And Separation Columns In Chromatography - A method of analyzing samples includes loading a sufficient quantity of the sample onto a trap column to overload the trap column; heating an analytical column and the trap column to a greater temperature than the analytical column; and pumping a solvent, to the trap column, having a solvent composition profile that, in cooperation with a temperature differential, causes at least some of the components to elute sequentially from the trap column to the analytical column and focus on the analytical column prior to eluting from the analytical column; or optionally: loading a small-molecule sample onto a cooled portion of an analytical column; heating the analytical column; and pumping a solvent, to the heated analytical column, to elute the components from the analytical column. Chromatographic separation includes: a trap column; a separation column; a trap-column heater; a separation-column heater; a solvent pump unit; and a control unit can be used.07-05-2012
20080280367Modulators Of NOD2 Signalling - The present invention relates to intracellular signaling molecules, in particular the Nod2 protein and nucleic acids encoding the Nod2 protein. The present invention provides methods of identifying modulators of Nod2 signaling. In particular, the present invention additionally provides methods of screening immune modulators such as adjuvants using Nod2. The present invention further provides methods of altering Nod2 signaling.11-13-2008
20100015717Mass Tags for Quantitive Analysis - The present invention relates generally to novel protein modification reagents for fractionation and quantitative (differential) profiling of proteins in a complex mixture. The reagents react with amino acids or other protein components or structures and function as mass tags. The present invention provides methods of making the protein modification reagents and methods of using the protein modification reagents for quantitative analysis of proteins.01-21-2010
20080213910METHOD FOR BLOCKING NON-SPECIFIC PROTEIN BINDING ON A FUNCTIONALIZED SURFACE - A method of blocking non-specific protein binding on surfaces, such as protein-coated biosensor surfaces.09-04-2008
20110053279DETECTION METHODS OF PROTEINS ON POLYACRYLAMIDE GELS USING GEL BACKGROUND STAINING AND ORGANIC DYE COMPOSITIONS FOR THE SAME - Disclosed are a method for detecting proteins on a polyacrylamide gel by background staining method using an organic dye composition containing eosin Y or phloxine B, and the organic dye composition for use in the method, which enables the rapid and simple detection of the protein on the polyacrylamide gel with a high sensitivity.03-03-2011
20100233819ROBO: A NOVEL FAMILY OF POLYPEPTIDES AND NUCLEIC ACIDS - Robo1 and Robo2 polypeptides may be produced recombinantly from transformed host cells from the disclosed Robo encoding nucleic acids or purified from human cells. The invention provides isolated Robo hybridization probes and primers capable of specifically hybridizing with the disclosed Robo genes, Robo-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.09-16-2010
20110111512QUANTITATION OF INSULIN-LIKE GROWTH FACTOR-I AND INSULIN-LIKE GROWTH FACTOR-II WITH HIGH-RESOLUTION MASS SPECTROMETRY - Methods are provided for determining the amount of an IGF-I and/or IGF-II protein in a sample using high resolution/high accuracy mass spectrometry. The methods generally comprise enriching an IGF-I and/or IGF-II protein in a sample, ionizing an IGF-I and/or IGF-II protein from the sample to generate IGF-I and/or IGF-II protein ions, and determining the amount of IGF-I and/or IGF-II protein ions with high resolution/high accuracy mass spectrometry.05-12-2011
20110136244METHODS AND KITS FOR A COLOR CHANGING SAMPLE DILUENT - The present invention provides methods and kits in assessing color change in a series of reaction mixes while providing significant improvement in the amount of non-specific binding. The method provides for a dramatic color change when incorporated into a series of assays or used in an individual reaction. The color change enables quick visual tracking and verification of the addition of reaction components. Further, the color change allows for verification that an instrument is performing correctly in reagent addition during an automated assay. In one embodiment, the reaction mix is initially a yellowish color. Upon adding serum or plasma, the resulting solution undergoes a dramatic color change to blue-purple, allowing for easy visual verification. Color change depends upon pH shifts in the sample preparation upon addition of serum or plasma. The method is useful whenever two or more reagents are combined and confirmation of the combination is required.06-09-2011
20100311176METHOD OF MASS ANALYSIS OF TARGET MOLECULES IN COMPLEX MIXTURES - The present invention is a method for performing a mass spectrometric analysis of analytes in a complex mixture. In particular, samples containing unknown analytes are analyzed by MS/MS to identify portions of a molecule of interest that has been labeled with a selected isotope. Ionization and detection identify a characteristic isotope shift in real time based on a selective precursor ion scan that in turn identifies precursor masses that also contain the isotopic shift. From the precursor ion scan, precursor masses are identified for further mass spectrometric analyses. The method of the invention is preferably performed in real time such that the precursor ion scan simultaneously identifies target precursor ions and identifies precursor masses for further analyses.12-09-2010
20100311177Fluid sample collecting and analyzing apparatus and method - A spongy swab (12-09-2010
20100330683METHOD FOR QUANTIFYING OXIDATIVE STRESS CAUSED BY DIFFERENT BIOLOGICAL PATHWAYS - The present invention relates to methods for detecting a oxidative stress in a biological sample, methods of determining a cumulative record of oxidative injury, and methods of diagnosing diseases of aging, such as cardiovascular diseases, based on the presence or absence of a biomarker or a component thereof. The present invention also relates to a kit for detecting oxidative stress in a biological sample comprising a stabilizing reactant and an antibody. In some embodiments of the invention, the biomarker of oxidative stress is selected from an aldehyde-protein adduct and an aldehyde metabolite-protein adduct, and the proposed method further comprises measuring separately for the same protein biomarkers of oxydative stress formed with different amino acids of the protein.12-30-2010
20100173418Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making - The present invention relates in general to polypeptides having reduced susceptibility to oxidation, methods of selecting or making the polypeptides and methods of use thereof. The polypeptides having reduced susceptibility to oxidation are modified by amino acid substitution, deletion or insertion to confer reduced susceptibility to oxidation, thereby decreasing degradation of the polypeptide and extending the shelf-life and biological activity of the polypeptide under typical storage, handling and use conditions.07-08-2010
20100261282Method of evaluating IGT, IGT-evaluating apparatus, IGT-evaluating method, IGT--evaluating system, IGT-evaluating program, recording medium, and method of searching for prophylactic/ameliorating substance for IGT - According to the method of evaluating IGT of the present invention, amino acid concentration data on concentration values of amino acids in blood collected from a subject to be evaluated is measured, and an impaired glucose tolerance state in the subject is evaluated based on the measured amino acid concentration data of the subject.10-14-2010
20090176310DETECTION PROCEDURES FOR FIBRINOGEN AND/OR FIBRINOGEN DERIVATIVES - Described are determination procedures for fibrinogen and/or fibrinogen-derivatives by matrix-independent turbidimetry. In the FIFTA called procedure the fibrinogen activity is preferably determined in an undiluted sample by addition of thrombin and/or albumin, as well as polybrene if appropriate, in PBS and determination of the increase in absorbance at 405 nm. In the FIATA called procedure the fibrinogen-concentration and/or the concentration of fibrinogen-derivatives is preferably determined by addition of vancomycin and determination of the increase in turbidity at 405 nm. It is standardized by usage of plasma standards of known fibrinogen-activity and/or fibrinogen-concentration.07-09-2009
20090197344METHOD FOR THE PREDICTION OF VASCULAR EVENTS AND THE DIAGNOSIS OF ACUTE CORONARY SYNDROME - The present invention relates to a method for the prognosis of a vascular event or the diagnosis of ACS in a patient suspected of being at risk for a vascular event or condition, said patient presenting: 08-06-2009
20090197343METHODS FOR DETECTION OF PATHOGENIC PRION PROTEINS ASSOCIATED WITH PRION DISEASES, USING CONJUGATED POLYELECTROLYTES - The present invention relates to a method for detecting the presence of a pathogenic prion species in a sample comprising the steps—bringing the sample in contact with at least one conjugated polyelectrolyte (CPE)—irradiating the CPE with electromagnetic radiation—measuring the radiation emitted or absorbed by the CPE at at least one wavelength, and—comparing the measured emitted or absorbed radiation to at least one reference value corresponding to the CPE interacting with a known prion species. Optionally, the emitted or absorbed radiation is measured at least two wavelengths and a ratio is formed of the values of the measured radiation. The method facilitates differentiation between different strains of pathogenic prion species. The invention also relates to devices for performing the method.08-06-2009
20100190261PROTEIN ANALYSIS METHOD USING ISOTOPE COMPOUND AS LABEL - The present invention provides a protein analysis method using a combination of two or more kinds of stable isotopes of a compound represented by the formula (I):07-29-2010
20100190262DIAGNOSTIC AGENT FOR URINARY PROTEIN OF CAT - A method for diagnosing a kidney disease in a cat by detecting a cat urinary protein without being affected by cauxin, and a diagnostic agent therefor are provided. A method of detecting a urinary protein derived from renal dysfunction in a cat according to claim 1, wherein cauxin is removed from cat urine by bringing the cat urine into contact with a lectin or an anti-cauxin antibody that specifically binds to cauxin.07-29-2010
20100029005Method of Quantifying Membrane Protein By Using Mass Spectrometer - The present invention is to provide a method for quantifying a plasma membrane protein present in a cell membrane, by using a stable-isotope labeled peptide as a probe by mass spectrometry, in a simple, quickly and accurate manner. A plasma membrane protein is fragmented to prepare an oligopeptide fragment, identified by LC-MSMS, and by setting as essential criteria that the peptide is obtained by fragmentizing with a protease, and the peptide is specific to a target molecule, selective criteria with score are set for hydrophobic amino acids content, sequence conditions, number of amino acid residues, specific amino acid sequence conditions, etc. According to criterion for selecting a subject peptide for quantification for selecting preferentially a peptide with high score, a peptide fragment that can be ionized by ESI method is selected, and by using the subject peptide for quantification and a stable-isotope labeled peptide, the plasma membrane protein is quantified accurately by mass spectrometry.02-04-2010
20100029006MULTIPLEXED DIAGNOSTIC TEST FOR PRETERM LABOR - Embodiments of the present invention relate to methods and devices for evaluating a pregnant subject and/or identifying risk of preterm labor in the pregnant subject. The inventors have observed that the initiation of preterm labor or its likelihood in a pregnant patient who has not yet completed 36 weeks gestation can be evaluated by measuring levels of one or more biomarker (marker) that is indicative of labor and/or preterm labor in a sample from the patient.02-04-2010
20100022013DIRECT MASS SPECTROMETRIC ANLAYSIS OF AGGREGATES OF THERAPEUTIC PROTEINS - The invention relates to a method of using high-mass matrix assisted laser desorption-ionization (MALDI) mass spectrometry for the quantitative analysis of the amount of aggregation (dimers, trimers or multimers) of antibodies or other therapeutic proteins in purified pharmaceutical samples or complex biological matrices, as well as to the use of this method for characterization of antibodies, drug development and quality control of therapeutic proteins, including automated high throughput applications.01-28-2010
20100022014Method for Evaluating Obesity Controller - A method for efficiently evaluating or selecting an obesity controlling substance, a blood insulin regulating substance or a blood sugar regulating substance, is provided. A method for evaluating or screening an obesity controller, the method including administering a carbohydrate and a lipid to an animal, and evaluating or selecting a substance which decreases or increases insulin secretion, is also provided.01-28-2010
20080286875RYR2 MUTATIONS - This document provides methods and materials related to assessing a mammal for the presence or absence of a genetic mutation. For example, methods for determining whether or not a mammal contains a genetic mutation in an RyR2 sequence are provided. In addition, isolated nucleic acid molecules containing an RyR2 sequence and encoding a mutation are provided herein.11-20-2008
20090298185Protein Detection Reagents and Methods with Dyes and Dextrins - The invention provides reagents, methods and kits for detection of proteins and quantitative determination of protein concentration. The reagents comprise a protein-complexing dye, such as a Coomassie dye and one or more dextrins, for the elimination of interference caused by detergents.12-03-2009
20090298186Method to Assess Stability of Proteins - A method for determining conformational stability of proteins detects the change in free sulfhydryls accessible to reaction with a fluorescent probe after combined chemical and thermal denaturation. The method is useful in any application where the stability and integrity of a protein preparation is useful information. The method can be used to screen protein variants for desirable stability profile.12-03-2009
20110070653INHIBITOR OF HISTONE ACETYLTRANSFERASE, ESPECIALLY p300 - An inhibitor of histone acetyltransferase p300 was isolated from human cDNA library and identified as a nuclear protein composed of 855 amino acid residues. It binds to the cysteine/histidine-rich region of p300, thereby inhibiting the transcriptional activation by p300. It also inhibits the transcription activity of p53, with p300 functioning as a coactivator, and inhibits the discontinuance of cell cycle that relies on p53.03-24-2011
20090258427Method and Reagent Mixture for the Visualization of Amino Acids and Peptides - The invention relates to a method and reagent mixture for the staining and thus visualisation of amino acids, peptides and similar compounds, in particular after separation by means of thin-layer chromatography. The staining is carried out using NIN-HYDRIN for the detection of amino acids, peptides or proteins in combination with at least one ionic liquid.10-15-2009
20080286876GENES ASSOCIATED WITH ALZHEIMER'S DISEASE - Hltdip - A method of screening a small molecule compound for use in treating Alzheimers Disease, comprising screening a test compound against a target or targets selected from the gene products encoded by a group of specified genes, where activity against said target indicates the test compound has potential use in treating Alzheimers Disease.11-20-2008
20090104706CYTOKINE RECEPTOR MODULATORS, METHOD OF IDENTIFYING SAME, AND METHOD OF MODULATING CYTOKINE RECEPTORS ACTIVITY WITH SAME - The present invention relates to a method for identifying a non-competitive peptide, which inhibits the activity of a cytokine receptor. This method includes the steps of selecting a candidate peptide containing from about 7 to about 20 amino acids derived from a flexible region of a cytokine receptor, and determining the ability of the peptide to inhibit or promote the oligomerization and/or activation of the receptor by measuring an activity of the receptor in the absence or the presence of the candidate peptide, wherein the non-competitive peptide is selected when the activity of the receptor is measurably lower in the presence of the peptide as compared to in the absence of the peptide so identified. This invention also provides agonists of cytokine receptor activity. Pharmaceutical compositions that comprise the identified peptides are disclosed. Also disclosed are methods for treating patients with a disease or condition associated with abnormal cytokine receptor mediated function or activity such as inflammatory, autoimmune and vascular diseases.04-23-2009
20090104707ANALYTE DETECTION WITH MAGNETIC SENSORS - Methods for analyte detection with magnetic sensors are provided. Aspects of the methods include producing a magnetic sensor device having a magnetically labeled analyte from a sample, such as a serum sample, bound to a surface of a magnetic sensor thereof; and obtaining a signal, e.g., a real-time signal, from the magnetic sensor to determine whether the analyte is present in the sample. Also provided are devices, systems and kits that find use in practicing the methods of the invention. The methods, devices, systems and kits of the invention find use in a variety of different applications, including detection of biomarkers, such as disease markers.04-23-2009
20110151569IDENTIFICATION OF SAMPLE COMPONENTS - The present disclosure relates to the identification of components in a sample based on the chemical nature of the component. In particular, although not exclusively, the present disclosure relates to the identification of hydrophobic and hydrophilic components using a mass spectrometric technique. The present invention also relates to kits and products used in the identification of the components, as well as other subject matter.06-23-2011
20100240137DERIVATIZATION-ENHANCED ANALYSIS OF AMINO ACIDS AND PEPTIDES - The present invention provides compositions and methods for enhanced detection and quantification of amino acids by derivatization. Also provided are compositions and methods for enhanced detection and quantification of peptides by derivatization.09-23-2010
20090325302Diagnostic marker for diabetic vascular complications - The present invention relates to the discovery that CTGF is a diagnostic marker indicative of increased risk for development and progression of vascular disease.12-31-2009
20120301968MASS SPECTROMETRY METHOD - The problem to be solved by the present invention is to provide a method for treating a polypeptide including a cysteine residue for enhancing the sensitivity of detection thereof in mass spectrometry using charged particles. A mass spectrometry method for a polypeptide including a cysteine residue is provided which includes treating the polypeptide including a cysteine residue with a cyanation agent, treating the cyanated polypeptide with a base, and then desorption ionizing the base-treated polypeptides using charged particles for mass spectrometry.11-29-2012
20100317119Quenched Fluorophores Conjugated to Peptides Via Linkers Containing Dithio Groups - Disclosed are dithio compounds that include a quenched fluorophore and a non-fluorophore peptide linked via a dithio bond to the fluorophore. The dithio compounds may be used in methods for detecting thiol-containing compounds or dithio-containing compounds. The dithio compounds also may be used as cellular probes where the peptide portion of the compounds targets the compounds to a specific cellular location.12-16-2010
20100068818ALGORITHMS FOR MULTIVARIANT MODELS TO COMBINE A PANEL OF BIOMARKERS FOR ASSESSING THE RISK OF DEVELOPING OVARIAN CANCER - The present invention provides methods for assessing a patient's risk of having and/or developing ovarian cancer. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biological patterns in biological samples. The biological patterns are obtained using, for example, mass spectrometry systems and other techniques. The present invention also includes therapeutic and prophylactic agents that target the biomarkers described herein. Also, the present invention provides methods for the treatment of ovarian cancer using the markers described herein or agents that mimic the properties of these markers.03-18-2010
20120045841SYSTEM AND METHOD FOR GENERATION OF AUTOMATED DENATURATION GRAPHS - A system and method for creating a plurality of denaturation curves is disclosed. In accordance with certain embodiments, one variable, such as salt content, pH or another parameter, is varied to create a plurality of different buffer solutions. Each is then used to create a denaturation graph. The plurality of denaturation graphs allows analysis of the effect of that variable on protein stability.02-23-2012
20090148951Thyroglobulin quantitation by mass spectrometry - Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.06-11-2009
20120009685DESIGN OF A PEPTIDE PROBE FOR RAPID AND SPECIFIC DETECTION OF AMYLOID AGGREGATION - A peptide probe that generates fluorescence signals rapidly upon recognition of various Aβ aggregates without significant perturbation of samples. The present peptide probes display an increase in fluorescence signals upon coincubation with Aβ oligomers, but neither monomeric/dimeric species nor fibrils. The detection can occur within an hour or two without any additional sample preparation and incubation steps.01-12-2012
20120058565CONJUGATES OF 1,4,7-TRIAZACYCLONONANES, DINUCLEAR METAL COMPLEXES OF SUCH CONJUGATES, AND METHODS OF USE FOR BOTH 1,4,7-TRIAZACYCLONONANES AND CONJUGATES - Conjugates of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes with a variety of conjugating members are used in the formation of dinuclear metal complexes which bind to phosphate esters. By virtue of their conjugated forms, the complexes are incorporated into chromatographic media, affinity binding reagents, and dyes, which make the complexes useful in a wide range of assays, separations, and purifications. In addition, dinuclear metal complexes of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes that are not so conjugated are used in the detection of phosphate esters of biological species by either MALDI-TOF mass spectrometry or by dye displacement.03-08-2012
20110091981Mass Spectrometry Quantitation of P450 Isoforms in Hepatocytes - A method for screening a drug for cytochrome P450 (CYP) induction is provided and can include incubating the drug with a microsome-containing biological sample and then quantitating at least one cytochrome P450 isoform. The isoforms can be selected from 2B6, 3A4, 1A2, and 3A5 isoforms. In some embodiments, the method uses liquid chromatography tandem mass spectrometry (LC-MSMS). A quantitated value can be compared to a threshold value and the drug can be determined to exhibit an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. Isolated peptides are also provided.04-21-2011
20110039343METHOD FOR THE IDENTIFICATION OF PATIENTS IN NEED OF THERAPY HAVING MINOR COGNITIVE DISORDERS AND THE TREATMENT OF SUCH PATIENTS - A method for the identification of patients in need of therapy and for the preventive treatment of such patients having minor cognitive disorders, wherein an increased risk can be determined for said patients to develop clinically manifested Alzheimer's disease during a preceding risk stratification as a result of an increase in circulation-relevant peptide biomarkers measurable in the circulation of said patients, using drugs that comprise one or more active ingredients of cardiovascular agents, which are selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, betablockers and blood pressure-lowering diuretics and the combinations thereof, or using drugs comprising one or more ANP receptor antagonists or one or more adenosine receptor antagonists.02-17-2011
20110039341Method for detecting nucleotide polymor-phisms using semiconductor particles - A method for detecting anomalies in genetic material is provided, the method comprising supplying the genetic material; establishing electronic communication between the genetic material and a semi-conductor particle so as to create a composite; contacting the composite with a first metal ion; and subjecting the contacted composite to energy in an amount and for a time sufficient to reduce the first metal ion to a first elemental metal. Also provided is a device for detecting single nucleotide mismatching in genetic material, the device comprising a semiconductor particle; a ligand attached to the particle; the genetic material in electronic communication with the ligand so as to form an organic-inorganic composite; metal ion in electronic communication with the composite, such that the metal ion reduces to elemental metal when the semiconductor particle is exposed to radiation of a predetermined energy level.02-17-2011
20110065197DIAGNOSTIC KIT FOR ALZHEIMER'S DISEASE, DIAGNOSTIC MARKER, AND DETECTION METHOD FOR INDICATOR OF PATHOLOGICAL STATE THEREOF - [Problems] The differential diagnosis of Alzheimer's disease as distinguished from other type of dementia and the diagnosis of Alzheimer's disease at such an early stage where neural cell death has not proceeded yet are important for the treatment of Alzheimer's disease. On the other hand, it is difficult to differentially diagnose Alzheimer's disease at an earlier stage by a diagnosis mainly made by questioning by a doctor or a diagnostic technique using phosphorylated tau or amyloid-β protein as an indicator. Thus, the development of a novel diagnostic technique has been demanded.03-17-2011
20110065199Atherosclerosis marker and use thereof - Since atherosclerosis induces cerebral infarction and myocardial infarction, a method for diagnosing or predicting atherosclerosis with the use of, as indicators, markers (factors) that allow early detection and progression prediction of the disease and a method for evaluating preventive or therapeutic effects have been awaited. This invention provides a method for diagnosing or predicting atherosclerosis which comprises detecting CD166 (ALCAM) level in a sample of a subject such as human, a method for evaluating preventive or therapeutic effects of a compound on atherosclerosis, and a kit and an apparatus for carrying out such methods.03-17-2011
20110065196Trityl Derivatives for Enhancing Mass Spectrometry - The present invention provides a method of forming an ion of formula (I) comprising the steps of: (i) reacting a compound of the formula (IIa); with a biopolymer, B03-17-2011
20110065198NOVEL TARGETS AND COMPOUNDS FOR THERAPEUTIC INTERVENTION OF HIV INFECTION - Novel drug targets and antiviral agents are provided for the therapeutic intervention of lentiviral diseases, in particular AIDS.03-17-2011
20110104813DIAGNOSIS OF EARLY STAGE CARDIAC DYSFUNCTION - Described are methods and devices for diagnosing heart failure in a subject based on the amount of brain natriuretic peptide (BNP) in a urine sample. Also described are methods and devices for predicting whether a subject is at risk of developing cardiovascular events accompanied with heart failure based on the amount of BNP in a urine sample.05-05-2011
20100093102MESOPOROUS METAL OXIDE MATERIALS FOR PHOSPHOPROTEOMICS - The present invention provides methods and materials for isolating, purifying, and/or enriching the concentration of compounds having one or more phosphate groups and/or derivatives thereof, including but not limited to phosphorylated peptides and/or phosphorylated proteins. In some aspects, the present invention provides nanostructured enrichment materials, such as metal oxide mesoporous materials, that selectively and reversibly bind with phosphorylated compounds with high specificity and are capable of controlled release of phosphorylated compounds bound to their active surfaces. Mesoporous materials of the present invention also provide enrichment materials having large active surface areas that provide for higher loading capacities for phosphorylated peptides and proteins relative to conventional affinity based methods. Nanostructured metal oxide mesoporous enrichment materials of the present invention are also compatible with implementation via a variety of separation platforms including flow through separation systems, elution based separation systems, column chromatography and affinity chromatography.04-15-2010
20090130769Novel Cross-Linkers For Obtaining Structure Information On Molecule Complexes - The present invention describes a novel cross-linker, a method for preparing one or more cross-linked biomolecules, biomolecular complexes of two or more biomolecules, a method for preparing cross-linked fragments from such cross-linked biomolecules and/or biomolecular complexes, a method for cleavage and reduction of such cross-linked biomolecules and/or biomolecular complexes, a method for identifying cross-links in such cross-linked biomolecules and/or biomolecular complexes, as well as a method for determining relative amounts of cross-links in a biomolecule or biomolecular complex in two or more samples.05-21-2009
20110183427METHOD FOR SEPARATING THE CONSTITUENTS OF A COMPLEX MIXTURE OF PROTEINS TO SUBMIT TO PROTEOMIC ANALYSIS AND APPARATUS THEREFOR - A method and an apparatus for separating the constituents of a complex mixture of proteins, for example an organic fluid, such as blood plasma, to submit to proteomic analysis. The method comprises, in particular, a step of distributing the complex mixture of proteins on a determined number n of separation elements different from each other (07-28-2011
20110183426Methods for Chemical Equivalence in Characterizing of Complex Molecules - The present invention provides for a method of characterizing and classifying a sample containing a complex molecule, such as a peptide or polypeptide mixture, protein, protein mixture, biologic and biosimilar by using physical analysis, such as mass spectrometry, and statistic methods.07-28-2011
20110183425Protein Complexes and Screening Methods - The application concerns an isolated protein complex comprising polypeptide components: (i) UTP20 HUMAN or a fragment, variant or homologue thereof; (ii) PWP2 HUMAN or a fragment, variant or homologue thereof; (iii) WDR46_HUMAN or a fragment, variant or homologue thereof; (iv) UTP18 HUMAN or a fragment, variant or homologue thereof; (v) MPPIO HUMAN or a fragment, variant or homologue thereof; (vi) WDR3_HUMAN or a fragment, variant or homologue thereof; (vii) TBL3 HUMAN or a fragment, variant or homologue thereof; (viii) WDR36_HUMAN or a fragment, variant or homologue thereof; and (ix) N0C4L HUMAN or a fragment, variant or homologue thereof. The application further concerns a method of identifying an agent that modulates the amount, function, activity, composition and/or formation of said protein complex; a method for the prevention or treatment of an eye disorder comprising administering to a subject in need thereof a suitable quantity of an agent that modulates the amount, function, activity, composition and/or formation of said protein complex; and a method of assessing whether a subject has or is likely to develop an eye disorder comprising determining whether the subject has an altered amount, function, activity, composition and/or formation of a protein complex.07-28-2011
20120164741QUANTITATION OF INSULIN BY MASS SPECTROMETRY - Methods are described for determining the amount of insulin in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying insulin in a biological sample utilizing purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.06-28-2012
20090311794DENATURATION CONTROL - The invention provides a method for monitoring the degree of protein denaturation and aggregation during the course of a heat treatment process comprising the steps of: 12-17-2009
20100210021PROCESS AND MARKERS FOR THE DIAGNOSIS OF KIDNEY DISEASES - A process for the diagnosis of kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.08-19-2010
20100047915IDENTIFYING PATIENTS AT RISK FOR LIFE THREATENING ARRHYTHMIAS - The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed.02-25-2010
20100047914AGENT DETECTION AND/OR QUANTITATION IN A BIOLOGICAL FLUID - A method of assessing retinal disease in an eye of a patient by rapid, point of care, quantitative detection of cytokine levels is provided.02-25-2010
20080199965Method For The Identification Of Proteins Folding Inhibitors - The present invention relates to a method for the identification of peptide inhibitors of the folding and thus of the biological function(s) of proteins which do not create resistance. In particular, the invention relates to inhibitors of viral enzymes with a high mutation rate.08-21-2008
20100273268DETERMINING ATHEROSCLEROTIC LOAD USING PLACENTAL GROWTH FACTOR - Disclosed are diagnostic methods relating to atherosclerosis. Specifically, methods are disclosed for diagnosing the arteriosclerotic load of a subject comprising determining the amount of PlGF in a sample of a subject and calculating the ratio of the determined amount and the upper limit of normal for PlGF, wherein a ratio of 1 indicates a normal arteriosclerotic load, a ratio less than 1 indicates a reduced arteriosclerotic load and a ratio larger than 1 indicates an increased arteriosclerotic load. The present invention also contemplates a method for identifying a subject in need of prevention or therapy of arteriosclerosis. Further, devices and kits are disclosed for carrying out the methods.10-28-2010
20100009453METHOD FOR DETERMINATION OF PRESENCE OR ABSENCE OF PEPTIDE COMPOUND PYY3-36 - The present invention provides a method for determining in a pharmaceutical test formulation the presence or absence of a peptide compound PYY01-14-2010
20100009452Functional Peptide Having Activity of Stimulating Immune Cell - A peptide having a sequence which satisfies all of the following requirements (I) to (V) and has an activity of stimulating an immune cell: (I) the number of constituent amino acid residues is 12 to 36; (II) the sequence is amphipathic; (III) the charge of the whole molecule is +2 or more; (IV) when constituent amino acid residues are arranged so as to form an a-helical structure, a side chain of any aromatic amino acid residue is not located between side chains of at least two positively charged amino acid residues on a side where hydrophilic amino acid residues are located; and (V) the sequence contains an amino acid residue which serves as a cleavage point for a mitochondrial processing enzyme.01-14-2010
20090061524Enzyme-Channeling Based Electrochemical Biosensors - Low-cost, non-toxic and fast immunoassay systems (immunosensors) and uses thereof as analytical and diagnostic tools for detecting an immune response in a subject are disclosed. The systems and methods disclosed are based on recording an electrochemical signal which is generated proportionally to an enzymatic cascade reaction (enzyme-channeling) upon detecting an analyte, and therefore can be used to determine the titer level of an antibody analyte in a liquid sample such as artificial media, serum or blood both qualitatively and quantitatively, in a one-step and separation free immunoassay. Systems and methods based on recording an electrochemical signal which is generated proportionally to an enzymatic cascade reaction (enzyme-channeling) upon detecting an analyte, which utilize a non-toxic secondary substrate such as acetaminophen are also disclosed.03-05-2009
20090061525ON-CHIP ANALYSIS OF COVALENTLY LABELLED SAMPLE SPECIES - A method for analyzing a sample comprising different sample compounds is described. The method comprises staining the sample compounds by adding a dye species to a solution of the sample, the dye species having reactive groups adapted for forming covalent bonds with specific groups of the sample compounds, and providing the modified sample compounds to a microfluidic chip, the microfluidic chip being adapted to provide an electrophoretic separation. The method further comprises electrophoretically separating the modified sample compounds, and detecting separated compounds.03-05-2009
20090311793Method of Esterifying Bio-Related Molecule for Mass Spectrometry and Method of Mass Spectrometry of Obtained Esterified Derivative - [Problems]To provide a method for enhancing analysis sensitivity of bio-related molecules in mass spectrometry. To provide a method for rapidly and conveniently analyzing biological acid molecules using the method of enhanced analysis sensitivity in mass spectrometry. 12-17-2009
20100267151MISFOLDED PROTEIN SENSOR METHOD - A catalytic conformational sensor method for detecting abnormal proteins and proteinaceous particles. The method is based on the interaction of a peptide fragment or probe with an abnormal proteinaceous particle. The interaction catalyzes the transformation of the probe to a predominately beta sheet conformation and allows the probe to bind the abnormal proteinaceous particle. This in turn, catalyzes the propagation of a signal associated with the test sample-bound probe. As a result signals can be propagated even from samples containing very low concentrations of abnormal proteinaceous particles. The peptide probes can be designed to bind to a desired peptide sequence or can even be based on dendrimer structure to control further aggregate propagation.10-21-2010
20110003392System and Method for Magnetically Concentrating and Detecting Biomarkers - System and method for capturing, concentrating, and detecting a diagnostic target in a liquid, comprising applying a magnetic field to a mixture comprising a co-aggregate in the liquid to provide a collected co-aggregate in the liquid, wherein the co-aggregate comprises a magnetic particle having a stimuli-responsive polymer attached thereto and a non-magnetic particle having a stimuli-responsive polymer and a diagnostic target attached thereto.01-06-2011
20110039342DIAGNOSTIC MARKERS OF WOUND INFECTION - A method of diagnosis or prediction of infection of a mammalian wound, said method comprising the step of detecting the presence of a cytokine selected from the group comprising procalcitonin, amino procalcitonin (N-ProCT), eotaxin, granulocyte macrophage colony stimulating factor (GM-CSF), interleukins IB monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1a), regulated upon activation normal T expressed and secreted (RANTES) in fluid taken from the wound. Also claimed is the device for use in the method.02-17-2011
20100203647Chemical Reporters of Protein Acylation - Methods and kits for detecting acylated proteins produced by cells that have been cultured or by cells within an organism are provided. Also provided are methods and kits for detecting acylated proteins produced by cells where affinity purification tags are that facilitate detection are used. Compounds useful for the detection of acylated proteins are also provided.08-12-2010
20100203646Process for Re-Coating of a Silica Gel Material - The present invention relates to a process for re-coating of a silica gel material with a coating, especially re-coating of an already used or spent coated silica gel material, and the re-coated silica gel material obtainable by the process, and uses thereof.08-12-2010
20100203645NOVEL ZWITTERIONIC DYES FOR LABELING IN PROTEOMIC AND OTHER BIOLOGICAL ANAYLSES - The invention relates to compositions and methods useful in the labeling and identification of proteins. The invention provides for highly soluble zwitterionic dye molecules where the dyes and associated side groups are non-titratable and maintain their net zwitterionic character over a broad pH range, for example, between pH 3 and 12. These dye molecules find utility in a variety of applications, including use in the field of proteomics.08-12-2010
20110217785CHITOSAN-COATED WIRES FOR BIOSENSING - A method of forming a bioelectronic device including a protein on an electrically conductive substrate, by electro-depositing aminopolysaccharide chitosan on the substrate while applying a cathodic voltage to the substrate, to form an aminopolysaccharide chitosan film thereon, applying an anodic voltage to the substrate in the presence of NaCl to activate the aminopolysaccharide chitosan film so that it is reactive with protein. The method also optionally includes reacting the aminopolysaccharide film, after activation thereof, with the protein, so that the protein assembles on and is coupled to the substrate, thereby forming a bioelectronic device. The protein can include single or multiple protein species, and including biosensing proteins. Additional methods include biosensing of electrochemically active compounds either present in a sample or generated during a biological recognition event and devices useful in such methods. The resulting devices are useful as sensors in hand-held devices, textiles, garments and the like.09-08-2011
20100233818Biological Load Indicator and Method of Measuring Biological Load - Disclosed are techniques capable of objectively and specifically evaluating various mental or physical conditions, of which evaluation was conventionally possible only by subjective symptom-dependent methods, such as stress and fatigue. Specifically disclosed are a stress or fatigue indicating agent including at least two factors selected from the group consisting of IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-γ, IFN-α, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF, CSF-2, TGF-β, neurotrophin 5, MCP-3, β-2-microglobulin, angiotensin II, CSF-3, CXC chemokine ligand 1, CXC chemokine ligand 5 and HGF; an agent for testing stress or fatigue including at least two molecules selected from the group consisting of molecules specifically recognizing the factors, respectively; a method of measuring stress or fatigue with the test agent; and an indicating agent for evaluating the intensity of mental conditions or disorders, including at least two factors selected from the factor group, wherein each of the factors is weighted.09-16-2010
20120276642USING SQUARAINE DYES AS NEAR INFRARED FLUORESCENT SENSORS FOR PROTEIN DETECTION - Squaraine dyes are used to detect the presence of protein in a test sample, which is a substance that may contain protein. A squarine dye is placed in water, and in some instances joined with an aggregation agent, to create an aqueous dye solution. That dye solution is joined with a test sample. When the dye solution is joined with the test sample and the resultant test solution is excited by the application of photons, a resulting fluorescence or absence thereof reveals if protein was present in the test sample.11-01-2012
20100216250Methods for Predicting Trisomy 21 in a Fetus - The present invention relates to biomarkers in maternal serum samples and methods for predicting whether a fetus has Trisomy 21 during the first trimester of pregnancy based on the differential expression of a combination, or subcombination, of the same.08-26-2010
20120329163MULTI-WELL PLATE WITH FILTER MEDIUM, AND USE THEREOF - A multi-well plate (12-27-2012
20120329162GENETICALLY ENCODED FLUORESCENT COUMARIN AMINO ACIDS - The invention relates to orthogonal pairs of tRNAs and aminoacyl-tRNA synthetases that can incorporate the coumarin unnatural amino acid L-(7-hydroxycoumarin-4-yl)ethylglycine into proteins produced in eubacterial host cells such as 12-27-2012
20100129918COMPOSITIONS AND METHODS FOR MONITORING BREAST CANCER TREATMENT - The present invention provides compositions and processes for preparing the same wherein the compositions are useful for monitoring breast cancer treatment.05-27-2010
20120149120CHIMERIC PROTEIN, METHOD FOR MANUFACTURING THE SAME, NANO-SENSOR IN WHICH THE CHIMERIC PROTEIN IS FIXED, AND APPLICATION THEREOF - There is provided a chimeric protein of capsid protein of Hepatitis B virus (HBV) and B domain of Staphylococcal protein A (SPA06-14-2012
20130017614METHODS AND KIT FOR ENDOMETRIOSIS DIAGNOSIS - An endometriosis diagnostic in which a biological sample of a female mammal having had a menstrual cycle within 90 days of the biological sample having been obtained from the female mammal is subjected to an in vitro diagnostic procedure in which the biological sample is contacted with an apatite compound for an effective time to provide a responsive visual appearance. Based on the visual appearance, a determination is made whether the female mammal has endometriosis.01-17-2013
20130017615PEPTIDE PROBE FOR RAPID AND SPECIFIC DETECTION OF AMYLOID AGGREGATION - A method for use of a peptide probe that generates fluorescence signals rapidly upon recognition of various Aβ aggregates without significant perturbation of samples. The present peptide probes display an increase in fluorescence signals upon coincubation with Aβ oligomers, but neither monomeric/dimeric species nor fibrils. The detection can occur within an hour or two without any additional sample preparation and incubation steps.01-17-2013
20110159600NATRIURETIC PEPTIDES AND ADIPONECTIN IN SUBJECTS WITH A METABOLIC SYNDROME - The present invention is concerned with a method for predicting the risk of mortality and/or a cardiovascular event in a subject who suffers from the metabolic syndrome based on the determination of a natriuretic peptide and adiponectin in a sample of a subject. Moreover, the present invention relates to a method for identifying a subject being susceptible to a therapy that intends to increase the level of adiponectin in a subject based on the determination of the aforementioned markers. Further disclosed are kits and devices adapted to carry out the method of the present invention.06-30-2011
20110159599Voltage Sensor Domains of Voltage-Dependent Ion Channel Proteins and Uses Thereof - A composition of matter suitable for use in identifying chemical compounds that bind to voltage-dependent ion channel proteins, the composition comprising a screening protein that comprises an ion channel voltage sensor domain of the ion channel protein immobilized on a solid support.06-30-2011
20110159598CRYSTAL STRUCTURE OF THE CCZ-LZ DOMAIN OF NEMO - The invention relates to a crystal of the CC2-LZ domain of the NEMO protein, in which the three-dimensional structure has been determined by X-ray diffraction at a resolution of about 3.25 A. The invention also relates to methods for the crystallisation of the CC2-LZ domain. The CC2-LZ crystals and the information derived from the crystalline structures thereof are used for identifying and designing compounds interacting with CC2-LZ.06-30-2011
20080248584Trityl derivatives for enhancing mass spectrometry - Compounds of formula (IIa):10-09-2008
20080241945Peptide for differentiating osteoarthritis from rheumatoid arthritis and non-disease conditions - A method for differentiation of osteoarthritis from rheumatoid arthritis and non-disease conditions in a sample, comprising measuring in the sample the concentration of a peptide comprising the 15 amino acid sequence (SEQ ID NO: 1) of the human cartilage intermediate layer protein 2.10-02-2008
20080227210Home test for glycated albumin in saliva - A home test for measuring glycated albumin levels in saliva. The saliva sample is collected at home using a standardized saliva collection kit and mailed to a testing laboratory that performs the test and reports the result directly back to the customer via the internet. The home test can be used to monitor glucose control in diabetics and in healthy individuals. It may also be used as a diagnostic aid in identifying individuals with diabetes, or who are at risk of developing diabetes.09-18-2008
20080220532Separation of Charged Solutes by Electrostatic Repulsion-Hydrophilic Interaction Chromatography - In one aspect, a method of performing electrostatic repulsion-hydrophilic interaction chromatography on a protein, peptide, or amino acid includes providing a column having an anion-exchange material at a pH of less than about 4, and eluting the compound using a mobile phase comprising an amount of organic solvent sufficient to substantially balance the electrostatic repulsion of the stationary phase with hydrophilic interaction. In another aspect, a method of performing electrostatic repulsion-hydrophilic interaction chromatography on a nucleic acid or nucleotide comprises providing a column having a cation-exchange material at a pH of less than about 3.4, and eluting the compound using a mobile phase comprising organic solvent sufficient to substantially balance the electrostatic repulsion of the stationary phase with hydrophilic interaction.09-11-2008
20110269241Methods And Kits For The Determining The Presence Or Absence Of Cyanobacteria Toxins - Embodiments of the present invention are directed to kits and methods for the detection of toxins produced by cyanobacteria. The methods and kits feature sample preparation steps with weak cationic and anionic exchange resins and small particle analytical columns operating at 4,000 to 15,000 psi.11-03-2011
20130102082PROTEIN CONCENTRATION ASSAY METHOD ANALYSIS TOOL AND ANALYZER - Provided is a protein concentration assay method that uses a protein indicating reagent and that enables highly accurate assay. The protein concentration assay method includes: optically analyzing a color exhibited after a sample to be assayed and a protein indicating reagent are brought into contact with each other; measuring pH of the sample to be assayed; and assaying a concentration of protein in the sample based on the result of the optical analysis, the measured value of pH, and data for protein concentration assay, wherein the protein indicating reagent is a protein indicating reagent whose color varies with pH and a concentration of protein, and the data for protein concentration assay include information indicating a way to assay the result of the optical analysis corresponding to the measured value of pH.04-25-2013
20130122598PROCESS FOR THE SPECIFIC ISOTOPIC LABELING OF METHYL GROUPS OF VAL, LEU AND ILE - The invention relates to a process for the specific isotopic labeling of Valine, Leucine and Isoleucine amino acids. The process of the invention uses a 2-alkyl-2-hydroxy-3-oxobutanoic acid in which the alkyl substituent in position 2 is ethyl or methyl. The invention can be used for the analysis of proteins, in particular by NMR.05-16-2013
20130130394DEVICES AND METHODS FOR CONTROLLING ACTIN FILAMENTS GROWTH AND ORGANIZATION USING MICROPATTERNED NUCLEATION SITES - The present invention concerns devices and methods for controlling actin filaments growth and organization with micro patterned nucleation sites, their uses for studying actin network formation, for screening of drugs or for preparing complex structures.05-23-2013
20100279421Systems and methods using photoluminescent nanostructure based hydrogels - Systems and methods related to compositions including hydrogels and photoluminescent nanostructures are described. The compositions can undergo a change in a physical, chemical, dielectric, or other property upon exposure to an altering stimulus. Changes in one or more properties of the hydrogel may impart a change in the photoluminescence of the nanostructures embedded in the hydrogel.11-04-2010
20110217784METHOD FOR PRODUCING SOLUBLE RECOMBINANT INTERFERON PROTEIN WITHOUT DENATURING - The present invention relates to the field of recombinant protein production in bacterial hosts. It further relates to extraction of soluble, active recombinant protein from an insoluble fraction without the use of denaturation and without the need for a refolding step. In particular, the present invention relates to a production process for obtaining high levels a soluble recombinant Type 1 interferon protein from a bacterial host.09-08-2011
20080199967System for Detection of S-Nitrosoproteins - The present invention describes a novel, simplified method for detecting and monitoring the presence of nitrosylated proteins, such as S-nitrosoproteins, in a biological sample using fluorescence detection. The present invention further describes a method which can both quantify and identify the nature of nitrosylated proteins, which method is useful for monitoring both normal and disease states, in the development and screening of potential therapeutic drug species.08-21-2008
20080199966Vitro Method For the Diagnosis of Neurodegenerative Diseases - An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample.08-21-2008
20100291694Crystal Structure of CRIg and C3B:CRIg Complex - The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.11-18-2010
20100317121PROTEIN SYNTHESIS MONITORING (PSM) - A method and a device are disclosed for monitoring the synthesis of proteins by the ribosome, wherein the ribosome is bound to a first label, for example a donor fluorophore, and a tRNA and/or amino acid are is bound to a second label, for example an acceptor fluorophore, wherein the first and second labels together from a FRET pair. As the ribosome mechanism processes the mRNA and tRNA molecules and synthesizes a polypeptide chain, a light source illuminates the ribosome, exciting the donor fluorophores and thereby the acceptor fluorophores whenever these are in sufficient proximity to a donor. The resulting signals are detected and used as a key for database searching and identification of the protein being synthesized.12-16-2010
20100317120Multiplexed Analyses of Test Samples - The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).12-16-2010
20110312099USE OF PSYCHROPHILIC ANAEROBIC DIGESTION IN SEQUENCING BATCH REACTOR FOR DEGRADATION OF PRIONS - The present invention relates to the use or process of use of a sequencing batch reactor for eliminating prion in specified risk materials and for measuring the efficacy of a sequencing batch reactor to degrade prion proteins in specified risk materials.12-22-2011
20130102081Detection and Characterization of Protein Degradation, Protein Degradation Modulation and Protein Degradation Modulators - Protein degradation, protein degradation modulation and protein degradation modulators can be detected and characterized through assessment of differential angular mobility exhibited by protein degradation reactants and products.04-25-2013
20090275142COMPOSITIONS AND METHODS FOR BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY - The invention provides compositions and methods for the detection of biological targets, (e.g. nucleic acids and proteins) by nucleic acid-templated chemistry, for example, by generating fluorescent polymethine dyes.11-05-2009
20120088307Methods and Compositions for Analyzing Proteins - Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification.04-12-2012

Patent applications in class PEPTIDE, PROTEIN OR AMINO ACID

Patent applications in all subclasses PEPTIDE, PROTEIN OR AMINO ACID